

# Index

---

---

*Note:* Page numbers in *Italics* refer to figures; those in **bold** refer to tables

- A498 cell lines, 423, **423**, **425–30**, 519  
Absorption spectroscopy, 371  
bis-Acetatoamminedichloro (cyclohexyl-amine)platinum(IV) (JM216), 499, 500  
Acetic hydrazide, 484  
Acetoxy-methyl-methyl-nitrosamine (AMMN), 134  
S-Acetyl N<sup>β</sup>-acetyldithiocarbazate (aadt), 402  
Acetyl-CoA carboxylase, 77  
2-Acetyl-furan semicarbazone, 406  
N-Acetyl-L-cysteine (NAC), 302, 304, 410  
2-Acetylnaphthalene semicarbazone, 406  
2-Acetylpyridine, 406  
bis(2-Acetylpyridine <sup>4</sup>N-dimethylthiosemicarbazone) gallium(III), gallium(III) tetrachloride, 271, 272  
2-Acetylpyridine phenylthiosemicarbazone, 478  
2-Acetylpyridine semicarbazone, 406  
2-Acetylpyridine thiosemicarbazones, 402  
2-Acetylthiophene semicarbazone, 406  
Acquired immunodeficiency syndrome (AIDS)  
    and Au drugs, 524  
    and Mn, 163, 169–70, 446, 448  
    and Zn supplementation, 244  
Acridine orange, 501  
Acrodermatitis enteropathica, 239  
Acromegaly  
    and Mn deficiency, 162  
Acute myocardial infarction, 57–60  
    and Mg, 57  
    and soft water, 57  
AcuTect<sup>®</sup>, 343  
Acyclovir, 502  
Adenine, 384, 387–8, 496  
Adenocarcinomas, 128–9, 134, 138, 196, 283, 409  
    *see also* Cancer; Carcinoma; Carcinosarcoma; Leukemia; Lymphomas; Melanoma; Sarcoma  
    breast, 220, 414  
    C13, 407  
    colon, 229, 382  
    lung, 137, 269  
Adenomas  
    colorectal, 119  
Adenosine monophosphate (AMP), 10  
Adenosine triphosphate (ATP), 55, 129, 153  
S-Adenosyl methionine, 306  
Adenomatous polyposis coli protein (APC), 6–7  
Adenyl cyclase, 5  
Adjuvants, 66–9  
Adolescence  
    and Ca homeostasis, 112

- Adriamycin, 282, 407  
 Advil<sup>®</sup>, 513  
 Affective disorders  
     and Mg, 61  
 Age-related macular degeneration (AMD)  
     and Sn, 435  
     and Zn, 243  
 Aging  
     and Ca homeostasis, 113, 113, **113**  
 AIDS, *see* Acquired immunodeficiency syndrome (AIDS)  
 Akti<sup>®</sup>, 512  
 Alanine, 138, 369  
     B analogues, 24  
 Albumin, 70, 129, 151, 172, 385, 514–15  
     human serum, (HSA), 547  
 Albuterol, 55  
 Alcoholism, 510  
 Algae, 96, 390  
     and Rh complexes, 388  
 Alginate raft formulations, 75–7  
 Alginic acids, 76, 76  
 Alginic salts, 76  
 Al(III) ions, 74–5  
 Alkali metals, 2  
 Alkoxide, 532  
 2-Alkoxyacroleins, 228  
 Alkylating agents, 23  
     chemotherapeutic, 22  
 Alkylgermatranes, 287  
 Allochrysin<sup>®</sup>, 512  
 Allochrysin<sup>®</sup>, 512  
 Allopurinol riboside, 454  
 Allyl selenide, 324  
 Allyl-3-hydroxypropyl selenide, 324  
 Alopecia  
     and Li, 15  
*Alternaria*  
     *alternata*, 405  
     *brassicae*, 405  
     *tenius*, 405  
 Altromycin B, 414  
 Alucap<sup>®</sup>, 74  
 Aludrox<sup>®</sup>, 70, 74  
 Alufibrate<sup>®</sup>, 77–8  
 Alum, 66–7  
 Alumina, 335  
 Alumino-silicates, 75  
 Aluminum, 85, 259  
     carbonate, 75  
     glycinate, 70  
     hydroxide, 66–70, 73–7  
     and metabolic diseases, 77–8  
     metallotherapeutics, 65–82  
     oxide, 66, 335  
     phosphate, 66, 68–9, 75  
     subacetate, 77  
     toxicity, potential, 79  
 Alzheimer's disease, 8, 12–14, 89  
     and Al toxicity, 79  
     and Tc dyes, 340  
 Amastigote kinetoplast-mitochondrion complex, 388  
 American cockroach, 93  
 American Heart Association guidelines, 60  
 Ames tests, 393  
 Amides, 189–90  
 Amineboranes, 42  
 trans-Amine(cyclohexylamine) dichloro-dihydroxoplatinum(IV) (JM335), 499–500, 500  
 Amines, 422, 468, 509  
     aliphatic, 476, 498  
     aromatic, 476  
     B-containing, 33, 33  
 Aminethiolate complexes, 469–70  
 Amino acids, 19, 87, 129  
     B-containing, 24–7, 26  
     carborane-containing, 26  
 $\alpha$ -Amino-3-hydroxy-5-methylisoxazole-4-propionic acid (AMPA), 13  
 2-Amino-6-ethoxybenzothiazole, 388–9  
 6-Amino-6-methylperhydro-1,4-diazepine-tetraacetic acid (AAZTA), 546, 547  
 D-Aminoacid oxidase, 515  
 Aminoborane, 475  
 Aminoethanesulfonate, 369  
 2-Aminonaphthothiazole, 389  
 $\alpha$ -Aminophosphonate, 284  
 tris(3-Aminopropyl)amine (trpn), 208, 208  
 2-Aminopyrimidine, 404, 410  
 2-Aminothiophenol, 384  
 Ammonia, 72  
 Amnesia, 79, 287  
 Amodiaquine<sup>®</sup>, 388, 389, 522  
 Amoxicillin, 182, 182  
 Ampicillin<sup>®</sup>, 431  
 Amyloid precursor protein (APP), 12

## Index

- Amyloid- $\beta$  peptides, 12
- Amyotrophic lateral sclerosis
  - and Mn deficiency, 162
- Anakinra, 166
- Analogues, sila, 92–3
- Anemia, 179, 269
  - Ga-induced, 269
- Angina, 484
- Angiogenesis, 71, 137, 305, 555
- Angioplasty, 484
- Angiotensin-converting enzyme (ACE), 95
- Anhydrases, 238
- Anorexia nervosa
  - and As, 298
  - and Zn deficiency, 241
- Anosmia
  - Zn-associated, 245, 251–2
- Antacids, 69–73, 80
- Anthracene-9,10-dione, 22
- Anthraquinones, 22
  - boronated, 23
- Anti-convulsants, 95
- Anti-flatulents, 94
- Anti-gene strategy, 373, 375
- Anti-hypertensives, 327
- Anti-inflammatory agents
  - Se-containing, 321–4
- Anti-malarial drugs, 78
- Anti-microbial agents, 96
- Anti-oxidants
  - Se-containing, 321–4
- Anti-perspirants, 94
- Anti-plasmodial agents
  - ferrocenyl, 191–3
- Anti-Polyribosyl Ribitol Phosphate, 69
- Anti-sense strategy, 373, 375
- Antibiotics, 73–4
  - see also* Drugs
- Antimonate, 442
- Antimoniotungstate, 446–7
- Antimonite, 442, 454
- Antimony, 443
  - citrate, 443
  - anti-leishmanial drugs, 444–5
  - basic properties, **442**
  - biological features and therapeutic aspects, **455**
  - chemistry, 441–3
  - cups (wine), **444**
  - bis(4,5-dihydroxybenzene-3,5-disulfonate), 444
  - drugs
    - historic view, 443–4
    - pharmacokinetics and clinical aspects, 448–9
    - pharmacology and human toxicology, 447–8
    - possible mechanism of action, 449–56
    - reduction, 449–50
  - formation of DNA-protein complexes, 453
  - haloantimony(III) complexes, 442
  - inhibition of topoisomerase I by, 453
  - interaction with biologically relevant molecules, 449–56
  - isotopes, 441
  - mediated cell death in *Leishmania*, 454
  - in medicine, 441–61
  - pentachloride, 443
  - reaction with thiolate compounds, 450–3
  - side effects, 447
  - sulfide, 279
  - tartrate, 445
  - toxicity, 447
- Antisense technology, 40–2
- Antiseptics, 80
  - topical, 77
- Apoferitin, 558, 558
- Apolactoferrin, 263
- Apoptosis, 12–13, 128, 224–5, 224, 248
  - As-induced, 300–6
  - cisplatin-induced, 494
  - Ga-induced, 264
  - Sb-induced, 447, 454
- Apyrimidic endonuclease (APE), 248
- Arabinosyl-2-fluoroadenine, 502
- Arginase, 160
- Argyrodite, 279
- Aristotle, 297
- Aromatic boronic acids, 21
- Arrhythmias, 60–1
- Arsenates, 299, **299**, 300

- Arsenic, 179, 441, 443, 452  
   absorption, distribution and excretion, 306  
   and activation of caspases, 305  
   biological features and therapeutic aspects, **455**  
   chemistry, 299  
   and collapse of mitochondrial membrane potential, 303  
   and down-regulation of bcl-2, 304  
   induction of ROS, 302–3  
   inorganic compounds, **299**  
   interaction with Se, 317–18  
   mechanisms of action, 300–6  
   and mechanisms of apoptosis, 305–6  
   metabolism, 306–7, 307  
   metallotherapeutic compounds, 297–311  
   modulation of PML and PML-RAR? genes, 301–2  
   and p53, 304–5  
   pharmacokinetic profiles, 306–7  
   and role of glutathione, 303–4  
   sulfide, 297  
   toxicity, 297, 447  
   trichloride, 443  
   trioxide, 297–309  
     indications and uses, 308  
     toxic side effects, 307–8  
     treatment of malignancies, 300  
 Arsenic acid, 299  
 Arsenious acid, 299  
 Arsenism, 317–18  
 Arsenites, 299, **299**, 300  
 Artemisinin, 191  
 Arthritis, 165–6, 267, **444**  
   *see also* Rheumatoid arthritis  
   and Mn, 163, 166  
   and SOD isoforms, 163  
 Arylgermatranes, 287  
 Arylpiperazines, 480  
 Arylsulfonamide, 553, 553  
 Ascorbate, 144, 154  
 Ascorbic acid, 304, 482–3  
*Asellus aquaticus*, 393  
 Aspartamide, 194  
 Aspartyl protease  $\beta$ -secretase (BACE), 12  
  
*Aspergillus*  
   *flavus*, 405  
   *niger*, 405, 522  
 Aspirin<sup>®</sup>, 514  
 Asthma, 54–5  
   bronchial, 523  
   and Se deficiency, 316  
 Atherosclerosis, 77, 80, 167, 284  
   and Se deficiency, 315  
 Atherosclerotic lesions, 168  
 Atrial fibrillation, 61  
 Atropins, 73  
 Auranofin<sup>®</sup>, 512–17, 522  
   analogues, 518–20  
 Aureotan<sup>®</sup>, 511  
 Auromyose<sup>®</sup>, 511  
 Aurothioglucose, 511, 512, 514  
 Aurothiopropanol sulphonate, 512, 512  
 Autoimmune diseases, 77  
 Autoimmune uveitis, 267  
 Avidin, 558–9  
 AZGY-83a cell lines, 414  
 Azides, 472  
 Azido, 410  
 Aziridines, 87  
 Azobenzene, 411  
 Azole, 405  
  
 B16-Nex2 cell lines, 410  
*Babesia microti*, 286  
*Bacillus*  
   *cereus*, 402, 405  
   *subtilis*, 402, 521–2, 537  
 Bacteria, 96, 263–4, 272, 289, 530  
   *see also* Drugs, anti-bacterial  
   inhibited by Pt, 489  
   and Pd complexes, 403–4  
   and Rh complexes, 388, 390  
   and Sn complexes, 431, 433  
 Bacterial SOS chromotest, 393  
 Bacteriophage RNA-polymerase, 367, 372  
 Balneotherapy, 168  
 Barbiturates, 39–40, 431  
   boronated, 40  
 Basaljel<sup>®</sup>, 75  
 Bax, 13–14

*Index*

- Bcl-2, 13–14  
     down-regulation, 304  
 Bel-7402 cell lines, 413  
 Benzene, 180  
 Benzenethiol, 89  
 Benzimidazole, 232  
     dithiocarbamate, 389  
 Benzimidazolium, 192–3  
 Benzimidazole, 388  
 Benzohydroxamic acid, 230  
 Benzonitrile, 369  
 Benzopyrimidines  
     hydroxoboryl isoesters, 28  
 Benzoylacetate, 130  
 Benzyl mercaptan, 89  
 2-Benzyl-1-naphthol, 323  
 S-Benzyl N<sup>β</sup>-[(5-nitrothiophene-2-yl)  
     methylene]dithiocarbamate  
     (bntdt), 402  
 6-(Benzylamino)-2-[(2-hydroxyethyl)  
     amino]-9-methylpurine (olomoucine),  
     414  
 6-(Benzylamino)-2-[(3-hydroxypropyl)  
     amino]-9-isopropylpurine (bohemine),  
     **221–2**, 414  
 6-Benzylaminopurine (BAP), **222**  
 S-Benzylthiocarbamate, 406, 409  
 Benzylgermatranes, 287  
 Benzylidenehydrazinecarbothiamide, 403  
 Benzylidenehydrazinecarboxamide, 403  
 N<sup>l</sup>-(2-Benzoyloxy-benzylidene) pyridine-2-  
     carboxamidrazone (pcm), 225, 225  
 Beryllium, **3**  
 Bib-Label Lithiated Lemon-Lime Soda, **3**  
 Bifunctional chelates (BFCs), 339  
 Biguanides, 145  
 Bile acid, 70  
 Bilirubin, 203, 433  
 Biliverdin, 203, 433  
 Biliversin reductase, 433  
 Bio-ceramics, 127  
 Bioisosterism, Ge/Si/C, 290  
 Biologically active molecules, 467, 469–71  
 Biphenic acid, 192  
*p*-Biphenylgermatranes, 287  
 Bipolar disorder (BD)  
     and Li, 1, 3–4, 10–12  
 2,2'-Bipyrazine (BPZ), 369  
 2,2'-Bipyridine, 380, 382–3, 532  
 2,2'-Bipyridyl (bipy), 228  
 Bismite, 530  
 Bismuth, 441, 443, 452  
     aluminum carbonate, 73  
     biological features and therapeutic  
         aspects, **455**  
     carbonate, 530  
     chloride, 530  
     citrate, 530, 532  
     development of bioactive compounds,  
         534–7  
     dithiolate compounds, 535  
     fundamental aspects of chemistry,  
         530–1  
     hydroxycarboxylate complexes,  
         531–4  
     interactions of compounds with  
         biological molecules, 537–8  
     magnesium–sodium–aluminum–silicate,  
         73  
     methods of characterization, 530–1  
     nitrate, 530  
     oxide, 530  
     pharmaceuticals, 529–40  
     salicylate complexes, 532  
     solubility of compounds, 530, 532  
     subcarbonate, 530  
     subcitrate, 530, 533, 535  
     subnitrate, 529  
     subsaliolate, 530  
     sulfide, 530  
     therapeutics, 529–30  
     thiosemicarbazones, 535  
     tris(esterthiolate)bismuth complexes,  
         535, 537  
     tris(methylthiosaliolate)bismuth  
         complexes, 535, 537  
     tropolone complexes, 535, 536  
 Bismuthinite, 530  
 2,2'-Bithienyl-germatranes, 287  
 Bland's veritable pills, 179  
 Bleomycin, 207, 283  
 Blistering diseases, 77  
 Bloating  
     and Ca supplementation, 122

- Blood pressure
  - high, and Ca metabolism, 116–18
- Blood urea nitrogen, 268
- Blood–brain barrier, 45, 55, 85, 174, 336, 542
- Body fat regulation, 119–20
- Bohemine, 221, **221**, 222, **222**, 414
- Bohr magneton, 545
- Bombesin, 471
- Bone
  - abnormalities and Mn deficiency, 162
  - disorders, 34
  - and Ga activity, 266
  - Mg in, 52, 61–2
  - mineral density (BMD), 61
- Boranes, 22, 475
  - phosphate esters, 32
- Borancarbonates, 42
- Boranonucleic acids, 42
- Boranonucleosides, 42
- Boroglycine, 24
- Borohydrides, 42
- Boron, **3**
  - analogues, 19
  - compounds for use in BNCT, 22–31
  - hydrides, 335
  - P-containing compounds, 31–3
  - <sup>10</sup>B delivery systems, 20
  - therapeutic compounds, 19–49
- Boron neutron capture therapy (BNCT), 19–21, **20**
  - compounds for use in, 22–31
- Boronic acid, 337
- p*-Boronophenylalanine (BPA), 21–2, 46
  - derivatives, 25
  - isomeric structure, 25
- Bovine immunodeficiency virus, 391–2
- Brachytherapy, 391
- Brain-derived neurotrophic factor (BDNF), 13
- British anti-Lewisite, 537
- 5-Bromo-2-thienylgermatrane, 287
- 3-Bromo-4-thienylgermatrane, 287
- Bromobenzylgermatranes, 287
- Brookhaven National Laboratory, 334–5
- Brugia pahangi*, 389
- BSH, 21–2, 45
- Budotitane, 127–8, **128**, 129–35
  - animal studies, 134
  - chemistry and anticancer activity, 130–1
  - clinical investigations, 134–5
  - crystallization, 133
  - isomer abundance, 131–3, **132**
  - reaction with biomolecules, 133–4
- Buthionine sulfoximine (BSO), 304
- Butylated hydroxyanisole, 302, 305
- (*S*)-4-*tert*-Butyldimethylsiloxy-2-cyclopenten-1-one, 87
- 7-*tert*-Butyldimethylsilyl-10-hydroxycamptothecin, 90
- 5-*O*-*tert*-Butyldimethylsilyluridine, 85, **86**
- t*-Butylhydroperoxide, 324
- Cabbage looper, 93
- Calcein AM assay, 220–1, **221–2**
- Calcitonin, 112, 267, 348, 484
- Calcium, 172
  - dietary, optimal amounts, 112–15, **114**
  - homeostasis, 110–11, **111**
  - and kidney stones, 121
  - metabolism, 34
  - metabolism, hormonal regulation, 111–12
  - metallotherapeutic role, 109–24
  - and osteoporosis, 115–16
  - oxide, 241
  - and parasite clearance, 454
  - and periodontal disease, 120–1
  - phosphate, 483
  - physiological roles, **110**
  - supplementation
    - benefits, 112–15
    - side effects, 121–2
  - and weight control, 119–20
  - and Zn deficiency, 241
- Calcium Polyp Prevention Study, 119
- Camptothecins, 89–90
- Cancer, 6, 166–7
  - see also* Adenocarcinomas; Carcinoma; Carcinosarcoma; Leukemia; Lymphomas; Melanoma; Sarcoma
- bladder, 138, 382
- BNCT treatment, 19–21
- bone, metastatic, 338

- breast, 183, 185, 223, 283, 382, 413
  - metastatic, 138
  - and SOD2, 161, 174
- cervical, 502
- colon, 93, 115, 119, 264, 318, **423**
- colorectal, 469, 491
- endometrial, 502
- gastric, 93
- gastrointestinal, 129
- head/neck, 129, 207
- liver, 469–70
  - metastatic, 93
- lung, 129, 285–6, 318, 414, **423**, 445, 499
  - high-risk, 249
  - non-small cell, 138, 286
- mammary, **423**
- and Mn, 163
- neck/head, 129, 207
- oral, 167
- ovarian, 91, 129, 286, 305, **423**, 489, 495
  - advanced, 502
  - relapsed, 499
- pancreatic, 499
- photodynamic therapy, 88–9, 130
- prevention by Se, 318–21
- proliferating cell lines, 263–4
- prostate, 95, 285, 303, 305, 318–19, 399
  - metastatic, 267, 483
  - and Zn, 249–51, 250
- renal, **423**
- Ru complexes in therapy, 359–78
- skin, 318, 434
- solar keratoses, 434
- testicular, 129, 207, 489
- and Ti exposure, 127
- urothelial, 502
- and Zn, 245–51
- Candida*, 183
  - albicans*, 91, 232, 521
  - tropicalis*, 537
- Carbamazepine (CBZ), 5, 11, 13
- 2-Carbamoylethylgermsesquioxane, 283
- Carbenicillin, 182
- Carbinols, 95
- Carbohydrates, 323
  - carborane analogues, 36
  - thiododecarborate-containing, 37
- Carbon dioxide, 76, 530
- Carbon monoxide, 203, 342, 466, 475
- Carbonic anhydrase, 553
- Carbonyl, 532
  - core approach, 474–9
- Carboplatin, 320, 413, 426, 490, 490
  - anti-tumor activity, 490–1
  - di-*n*-butyltin analogue, 425–6, 426
  - mechanism of action, 494–5
- Carborane cages, 21–2
- Carboranes, 22, 26, 345, 429
  - P-containing, 32–3
- Carboranylalanine
  - structure, 26
- closo*-Carboranylthiouracils, 39
- Carboxamidrazones, 225–7
- 4-Carboxyamido-3,2-hydroxypyridinone, 546
- Carboxydextran, 544
- 2-Carboxyethylgermanium sesquioxide, 280, 281, 282–4
- 2-Carboxyethylgermsesquioxane, 282–3, 288
  - anti-tumor activity, 283
- Carboxylates, 404, 476
- Carboxylic acid, 347, 424, 484
- Carcinoma, *see also* Adenocarcinomas; Cancer; Carcinosarcoma; Leukemia; Lymphomas; Melanoma; Sarcoma
  - basal cell, 434
  - bladder, 267, 283, 489
  - breast, 285, 410
    - BT-20, 413
  - cervix, 267, 285, 404
  - colon, 271, 409
  - colorectal, 285–6
  - Ehrlich ascitic, 230, 283–4, 380, 382
  - epidermoid, 404, 409
  - esophageal, 298
  - gastric, 286, 289
  - head/neck, 489
  - IMC, 288
  - KB, 382
  - liver, 413
  - lung, 489
    - Lewis, 283, 380
  - mammary, 271, 380

- Carcinoma (*Continued*)  
 oral, 380–1  
 ovarian, 267, 271, 285, 289,  
 407, 410  
 TG, 413  
 renal cell, 285, 409  
 squamous cell, 267  
 squamous tongue, 232  
 thyroid, 483  
 urothelial, 267
- Carcinosarcoma  
 ascitic, 265  
 Walker, 288
- Cardiac arrhythmia, 135
- Cardiac function  
 and Tc radiopharmaceuticals,  
 337
- Cardiac myocytes, 448
- Cardiolite<sup>®</sup>, 337, 337, 341
- Cardiomyopathy, 315–16  
 idiopathic, 174
- Cardiotec<sup>®</sup>, 337, 337
- Cardiotoxicity, 447–8
- Cardiovascular diseases, 167–8  
 and Mn, 163  
 $\beta$ -carotene, 243, 249
- Carrageenan, 170–1
- Casein kinase 1 (CK 1), 6
- Caspase-3, 13, 302
- Caspase activation, 305
- Catalases, 161, 171, 302
- Cataracts, 284  
 and Mn deficiency, 162
- $\beta$ -catenin, 6–7
- Cats  
 DM studies on, 148
- Celebrex<sup>®</sup>, 513
- Celecoxib, 513
- Celiac disease  
 and Zn deficiency, 241
- Cell signaling, 109
- Cell-mediated immunity (CMI), 66
- Centers for Disease Control and  
 Prevention (CDCP), USA,  
 448
- Central nervous system (CNS)  
 depressants, 39, 287  
 dopamine transporters, 340  
 severe symptoms, 53  
 spirogermanium toxicity, 285
- Cephalexin<sup>®</sup>, 431
- Cephalosporins  
 ferrocene-containing, 182
- Cephalothin, 182
- Cercopithicus*  
*aethiops*, 409
- Cerebrospinal fluid (CSF), 55
- Cerotec<sup>®</sup>, 336–7
- CH1 cell lines, 410
- Chagas disease, 523
- Chalcones, 192
- Chalybeate waters, 179
- Chemotherapy  
 Ru vasodilators/vasoconstrictors, 360  
 and SOD isoforms, 163
- Chick embryo  
 inhibited biosynthesis, 137
- Childhood Ca homeostasis, 112
- Chiron Hib-CRM<sub>197</sub> conjugate vaccine, 69
- Chlorella*  
*vulgaris*, 382, 390
- o*-Chlorobenzamide, 290
- 6-(2-Chlorobenzylamino)purine,  
 220, 221
- 6-(3-Chlorobenzylamino)purine, 220, 221
- 1-Chloro-2,4-dinitrobenzene, 322
- 1,3-bis-(2-Chloroethyl)-1-nitrosourea  
 (BCNU), 167
- 1-[*p*-bis( $\beta$ -Chloroethylamino)phenyl]-  
 2-amino-2-carboxyethylgermanium  
 sesquioxane, 283
- (2-Chloroethyl)*bis*(benzyloxy)methylsi-  
 lane, 96, 96
- N,N*-bis(2-Chloroethyl)diethylenetriamine  
 (DCD), 212–13, 213
- N,N'*-bis(2-Chloroethyl)ethylenediamine  
 (BCE), 211, 212
- N,N*-bis(2-Chloroethyl)ethylenediamine  
 (DCE), 211–12, 212
- 1-[(2-Chlorophenyl)diphenylmethyl]-1*H*-  
 imidazole, 389
- 1-(4-Chlorophenyl)-silatrane, 94
- Chlorpromazines (CPZ), 39
- 2-Chloropyridine, 389

- Chloroquine, 185–6, 186, 189–90, **190**,  
191, 389, 514  
diphosphate, 388, 523  
Chloroquine<sup>®</sup>, 78, 523  
Chlorosis, 179  
2-Chlorotetrahydrofuran, 83  
Chlorpromazine, 4  
CHO cell lines, 404, 410  
Cholesterol, 36, 77, 133, 162  
Chondroitin sulfate, 165–6  
Chrestien, 510  
Chromaffin cells, 327  
Chromatin  
Ti in, 129  
Chromium hexacarbonyl, 480  
5,6-Chrysenequinone diimine, 387  
Chrysotherapy, 511, 513, 515–16, 523–4  
Chymotrypsin, 202  
Cimetidine<sup>®</sup>, 71, 75  
Cisobitan<sup>®</sup>, 95  
Cisplatin, 127–9, 384, 399, 413, **423**,  
446, 490  
anti-tumor activity, 421, 489–90  
compared to budotitan, 134–5  
Ga potentiation, 269  
liposomal formulations, 501  
mechanism of action, 491–4, 492  
and other cytostatics, 193, 219  
Ru mimicking, 362–3  
side effects, 490  
similarities to Rh complexes, 380  
targeted, 501  
toxicity, 326, 361, 427  
Citrates, 129, 151–2, 172, 534  
and Al toxicity, 79  
Citric acid, 532  
and Sb, 442  
Clarithromycin, 530  
Clofibrac acid, 77, 78  
*Clostridium*  
*difficile*, 535  
Clotrimazole<sup>®</sup>, 389, 523  
CobalaFluors, 210–11, 210  
Cobalamin, 209, 210  
conjugates as drug-delivery devices,  
209–14  
<sup>11</sup>B conjugates, 209  
Cobalt, 201  
carbon bond sensitivity, 211  
complexes as potential pharmaceutical  
agents, 201–18  
<sup>55</sup>Co complexes, 213–14  
enzyme inhibition/induction, 202–4  
hypoxic selective agents, 211–13  
mercapopyridine-*N*-oxide, 214  
nucleic acid binding/cleavage, 204–9  
PET imaging agents, 213–14  
protoporphyrin, 203–4  
(II) [Co(tfa)<sub>2</sub>(happ)] complex, 206, 206  
(II) oxine, 214  
(III) bleomycin complexes, 206–8  
(III) PMAH complexes, 207–8  
(III) polyamine complexes, 208–9  
(III) polypyridyl complexes, 204–6  
(III) salicylaloxime (CoSAL), 203, 203  
(III) tropolonate, 214  
Coenzyme A, 384  
Colon  
and Mg absorption, 52  
Common cold  
and oral/nasal Zn supplementation, 245  
Congenital malformations  
and Mn deficiency, 162  
Conjonctyl<sup>®</sup>, 95, 96  
Constipation, 71, 73  
and Al–Mg antacids, 69  
and Ca supplementation, 122  
Contrast agents  
in MRI, 541–60  
PARACEST agents, 549  
responsive ('smart'), 548–54  
and enzymes, 552–4  
and pH, 549–51  
and redox potential, 551–2  
Copper, 172, 297, 400, 421, 508, 518  
benzohydroxamic acid complexes, 230  
chemotherapeutic compounds, 219–36  
chloride, 405  
deficiency, 251  
glucosone-bTSC complexes, 227, 227  
IC<sub>50</sub> values of complexes, 221–2, **221–3**  
imidazole derivatives complexes, 230–2  
polycarboxylate complexes, 233–4  
purine derivatives complexes, 220–3

- Copper (*Continued*)  
 sulfide, 279  
 thiosemicarbazone complexes, 223–30  
 (II) acetate, 232  
 (II) butanedioate, 232  
 (II) chloride, 232  
 (II) nitrate, 232  
 Copper zinc superoxide dismutase  
 (CuZnSOD), 161, 238  
 Corazol, 288  
 Coronary artery disease, 57–8  
 Coronary Artery Risk Development in  
 Young Adults (CARDIA), 120  
 COX-II enzyme inhibitors, 513  
 Cocksackievirus, 316  
 Creatinine, 268  
 elevated, 54  
 CremophorEL, 134–5  
 Crest<sup>®</sup>, 433  
 Crisino<sup>®</sup>, 512  
 Crisofin<sup>®</sup>, 512  
 Crohn's disease  
 and Zn deficiency, 241  
 C<sub>6</sub> cell lines, 410  
 Culpepper, N., 510  
 CX-1 cell lines, 410  
 Cyanide, 509  
 metabolites, 515  
 Cyanocobalamin, 209  
 Cyclen, 208, 208  
 Cyclic seleninate esters, 323–4, 324  
 Cyclodextrins, 139, 323, 382  
 1,5-Cyclooctadiene, 380  
 Cyclooxygenases, 323  
 Cyclopentadiene, 479  
 Cyclopentadienide, 345  
 Tc(CO)<sub>3</sub>, 344  
 Cyclopentadienylcarboxylic acid, 480  
 bis( $\pi$ -Cyclopentadienyl)titanium(IV)  
 dichloride, 135  
 Cyclopentadienyltricarboxylrhenium, 480  
 Cyclopentyl xanthate, 388  
 Cyclophosphamide, 137, 381, 514, 516, 517  
 Cyclosiloxanes, 95  
 Cysteine, 300, 383–4, 410, 452, 514,  
 520, 538  
 Cytarabine, 502  
 Cytidine, 133, 405  
 Cytochrome c, 14, 302–3  
 Cytochrome oxidase, 272  
 Cytokines, 55  
 anti-inflammatory, 66  
 pro-inflammatory, 165  
 Cytosine, 207, 404, 495–7  
 Cytosol, 184, 302  
 Cytotoxicity, *see also* Drugs, toxicity;  
 Nephrotoxicity  
 lung, 174  
 photoinduced, 500  
 of Sn compounds, 424, 427–30  
 testing (IC<sub>50</sub>), 229  
 testing organotin carboxylates, 423–5  
 Cytotoxins, 72  
 hypoxia-selective, 211  
 vacuolating (VacA), 72  
 Cytoxin<sup>®</sup>, 514  
 1,2-DACH diaqua platinum(II), 494  
 Daoy cell lines, 266  
 cis-DDP, 407–10, 412–14  
 De-Nol<sup>®</sup>, 530–1  
 Decamethylferrocenium tetrafluoroborate  
 (DEMFC<sup>+</sup>), 195–6  
 Decaphenylgermanocene, 281, 281, 288  
 Decarboxylases, 160  
 Deep vein thrombosis, 343  
 Deferoxamine, 264, 271  
 Dehydrocholic acid, 133  
 Dehydrogenases, 238  
 Deoxorubicin-RRD, 414  
 3-Deoxy-D-erythro-hexos-2-ulose  
 bis(thiosemicarbazone), 402  
 Deoxyribose, 207  
 2'-Deoxyuridine, 289  
 Depression  
 Li treatment, 3–4  
 Dermatitis, 162, 168, 393  
 and Mn, 163  
 Desferrioxamine, 172  
 Dextran, 544  
 Diabetes mellitus, 144, 168–9  
 and As, 298  
 and Ga, 267  
 and Mn, 163, 168

- type 1 and Zn, 244
- types 1 and 2, 144–5
- Diabetic nephropathy, 174
- 2,4-Di(O-Acetyl)-1,3,6-tri-O-(carboxyethyl)germanyl- $\beta$ -D-glucopyranose, 284
- Diacyl glycerol (DAG), 8
- Dialkyl-5,10,15,20-tetra-[3',5'-bis(*t*-butyl)phenyl]-porphyrinato-germanium(IV), 288
- Dialysis, 371–2
- Diamidine, 388
- 2,3-Diamino-1,4-naphthoquinone, 405
- Diaminodithiol, 339–40
- (1,2-Diaminoethane) dichloroplatinum (II), 501, 501
- p*-(4,6-Diamino-*s*-triazin-2-yl)aminophenylarsenoxide, 454
- cis*-Diamminecyclobutanedicarboxylatoplatinum(II), 490  
*see also* Carboplatin
- cis*-Diammine dichloro-platinum(II), 127, 361, 489  
*see also* Cisplatin
- trans*-Diammine dichloroplatinum(II), 495  
*see also* Transplatin
- cis*-Diammineglycolatoplatinum(II), 490  
*see also* Nedaplatin
- [(1*R*,2*R*-Diamminocyclohexane) oxalatoplatinum(II)] (1,2-diaminocyclohexane), 490
- Dianhydride, 484
- Diarrhea  
and Al–Ca antacids, 69  
travelers', 530  
and Zn deficiency, 240–1
- Diazenide, 473–4
- Diazepam, 54
- 1,2-Dibromoethane, 405
- Dicarbonyl(diphenyldithiocarbamato)-rhodium(I) complex, 380–1
- $\alpha,\beta$ -Dicarboxyethylgermesesquioxane, 283
- cis*-Dichlorodiammine platinum complex,  
*see* Cisplatin
- cis*-dichloromethionine, 410
- $\mu$ -oxo-dichlorotetrakis(1-phenylbutane-1,3-dionato)ditanium(IV), 130
- Dictyostelium*  
*discoideum*, and Li, 5, 8–9
- Dietary Approaches to Stop Hypertension (DASH), 118
- Di( $\eta^5$ -cyclopentadienyl)-iron(II), 180
- 5-(Diethoxyphosphoryl)-5-methyl-1-pyrroline *N*-oxide (DEPMPO), 195
- Diethyldithiocarbamate, 409
- Diethylenetriamine pentaacetate (DTPA), 252  
adenosylcobalamin, 209
- Diethylzinc, 280
- Di-Gel<sup>®</sup>, 70
- 4,5-Dihydro-1,3-benzene disulfonic acid, 302
- 5-(Dihydroxylboryl)-2'-deoxyuridine, 28
- Diketonates, 130–1
- meso*-2,3-Dimercaptosuccinic acid (DMSA), 483
- Dimethyl sulfoxide, 385  
as solvent, 423
- 2,9-Dimethyl-1,10-phenanthroline, 382
- 4,4'-Dimethyl-2,2'-bipyridine, 382
- 4,5-Dimethyl-*N*-(2-propenyl)-2-trimethylsilyl-3-thiophenecarboxamide, 91
- 2,2-Dimethyl-5-(5'-trimethylgermyl-2'-furfurylidene)-1,3-dioxane-4,6-dione, 288
- 2,2-Dimethyl-5-(5'-trimethylgermyl-2'-thienylidene)-1,3-dioxane-4,6-dione, 288
- Dimethylamine, 498
- 2-[(Dimethylamino)methyl]phenylgold (III)X<sub>2</sub>, 521, 521
- 4-(Dimethylamino)phenylgermatrane, 287
- 2-(3-Dimethylaminopropyl)-8,8-diethyl-2-aza-8-germaspiro[4,5]decane, 280–1, 285
- 4-Dimethylaminopyridine (dmap), 228
- Dimethylarsinic acid (DMA), 299, 300, 306
- N,N*-Dimethylformamide, 532
- Dimethyloctadecyl[3-(trimethoxysilyl)propyl]ammonium chloride, 96, 96
- 1,2-bis(Dimethylphosphino) ethane, 442
- Dimethylselenide, 314, 319
- Dimethylselenoxide, 319

- Dimethylsulfoxide, 362–4  
Dioxo complexes, 471  
4,4-Dioxo-3a,6a-dihydrothieno[2,3-d]isoxazoline-2, 289  
4,4-Dioxo-3-phenyl-5-trimethylgermyl-3a,6a-dihydrothieno[2,3-d]isoxazoline-2, 289  
Dioxygen, 207  
4,7-Diphenyl-1,10-phenanthroline, 382  
Diphenylene iodonium, 302  
2,6-*cis*-Diphenylhexamethylcyclotetrasiloxane, 95  
bis(Diphenylphosphino) ethane (dppe), 518  
Diphenylpyraline (DPH), 405  
Diphenylsilanediol, 95  
Diphosphines, 410  
Diphtheria, 80  
Dipicolinate, 148  
Dipyrido[3,2-*a*:2',3'-*c*]phenazine (dppz), 204, 205  
Direct labelling, 471–2  
Disease-modifying anti-rheumatic drugs (DMARDS), 514  
Disodium aurothiomalate, 511, 512, 514, 516, 520  
Distamycin, 501  
Distannoxanes, 427, 429–30  
Disulfonated 4,7-diphenyl-1,10-phenanthroline, 367  
1,1-bis(1,3-Dithian-2-yl)-1-germa-3-cyclopentene, 288  
Dithiocarbamates, 380, 409, 472, 519  
Dithiocarbazates, 400, 402–4, 472  
Dithiocarbazonic acid methyl ester, 535  
Dithiothreitol (DTT), 302–3, 552  
*N,N'*-Di-*p*-tolylformamidinate, 382  
Diuretics  
    and Zn loss, 252  
DNA, 208  
    binders, 22–4, 360–1, 387  
    boranophosphates in, 41  
    calf-thymus (CT), 371–2, 385, 392  
    cleavage, 208–9, 367  
    by Co complexes, 204–6  
    by Rh complexes, 387, 392  
    and photoelectron transfer, 368–71  
    gyrase, 453  
    modification by Pt drugs, 491–5  
    photocleavage, 204, 207–8  
    polymerases, 493–4  
    repair and Zn, 247–9  
    replication, 202–3  
    and Ru complexes, 366  
    Se-induced repair, 320  
    suppression, 286  
    synthesis, 262, 264  
    inhibition, 228, 361, 383, 390, 409, 493  
    and Zn deficiency, 246, 250–1  
Dogs  
    Ge toxicity studies in, 285  
Dopamine, 327  
     $\beta$ -mono-oxygenase, 327  
Dotarem<sup>®</sup>, 542, 543  
Doxorubicin, 209, 271, **423**, 427, 446, 502  
*cis*-DPP, 407  
Drugs  
    Al-containing, 65  
    analgesic, 431  
    anti-amebic, 402  
    anti-arthritic, 511–14, 516, 522  
    anti-bacterial, 88–9, 328, 382, 388–90, 405–6, 426  
    Bi-based, 534, 537  
    design, 202  
    trials, 431  
    anti-cancer, 19, 89, 360–1, 427, **444**  
    photoreactive Ru complexes, 365–72  
    anti-fungal, 89, 91, 406, 426, 537  
    anti-herpic, 405  
    anti-hypertensive, 327  
    anti-inflammatory, 15, 19, 80, 431, 516  
    anti-leishmanial, 444–5  
    anti-malarial, 522–3  
    anti-metastatic, 375  
    anti-microbial, 385, 400, 406, 432, 521–2  
    anti-muscarinic, 290  
    anti-osteoporotic, 19  
    anti-parasitic, 388–90  
    anti-secretory, 70  
    anti-trypanocidal, 433  
    anti-tumor, 144, 219, 379–88, 400, 407–14

Index

- Au, 517, 522
- Bi, 537
- Pt, 489–90
- Sn, 422–3, 426–30
- Ti, 125–42
- anti-viral, 144, 202, 327, 405, 501–2
- cardiovascular, 89
- CNS, 89
- cytostatic, 127
- cytotoxic, side-effects, 209
- Fe-based, 179–200
- heterobimetallic, 139
- hypolipidaemic, 19
- interactions, and Zn, 252
- melarsen, 454
- Mg, 53–62
  - motivation for development, 516–17
  - mucosal protection, 70
  - organoarsenic, 454
  - photoactive, 500
  - psychotropic, 4
  - Sb, 443–56
  - Se-based, 313–32
- DtaP vaccine, 69
- DTwP vaccine, 69
- Duodenum, 263
- Dyslipidemia, 57
- Dyspepsia, 73, 530
  
- Ebselen, 321–3, 321–3, 324, 328
- Eclampsia, 53–4, 118
  - Mg in, 54
  - phenytoin in, 54
- Edema, 118, 171
  - mucosal, 55
- Electrophoresis, 372
- Electrospray mass spectrometry (ESMS),
  - 371–2, 374, 452, 531
- Ellagitannins, 192
- Enbrel<sup>®</sup>, 166
- Encephalomyelitis, 85, 267
- Endocrine glands
  - Li accumulation in, 4
- Endocytosis, 558
- Endorem<sup>®</sup>, 544
- Endosomes, 555
- Endothelial cells, 58
  
- Endothelial dysfunction
  - and Mg, 53–4
- Entamoeba*
  - histolytica*, 400, 402, 404, 406
- Environmental Protection Agency (EPA), 160
- Enzymes
  - and Sb, 449–50
- Eosinophils, 55
- Eovist<sup>®</sup>, 542, 543
- Epidermis, 262
- Epilepsy, 11, 169
  - and Mn, 162–3
- Epithelium, 262
- EPR spectra, 152, 152
- Escherichia*
  - coli*, 164, 389–90, 402, 405, 453, 521, 535, 537
  - PQ37, 393
- Estradiol, 43, 183–5
- Estrogen
  - deficit, 116
  - receptors, 183–5, 226, 340
- Etanercept, 166
- Ethambutol, 252
- Ethionine, 404
- Ethoxide, 131
- 4-Ethoxyphenyl-[3-(4-fluoro-3-phenoxy-phenyl)propyl]dimethylsilane, 93
- Ethyl ethylamino-acetate dithiocarboxylate, 407
- (3-Ethyl-4-triphenylgermylisoazoliny-2-)-5-carboxylic acid ethyl ester, 289
- 9-Ethyladenine, 283, 384
- 7-Ethylcamptothecin, 91
- 1-Ethylcysteinyl, 336
- Ethylene, 96
  - dicysteine, 485
- Ethylenediamine-*N,N'*-bis[propyl(2-hydroxy-(*R*)-benzylimino)]aluminum (III), 78, 78
- Ethylenediamine-*N,N,N',N'*-terakis (methylene phosphonic acid) (EDTMP), 483
- Ethylenediaminetetraacetic acid (EDTA), 229
- 9-Ethylguanine, 382–3, 384

- Etidronate, 267  
 Etofenprox, 93  
 Etoposide, 209, 269, 407, **423**, 502  
 Europium, 556  
 EVSA-T cell lines, 423, **423**, **425-30**  
 Extended X-ray absorption fine structure (EXAFS), 483
- F10 cell line, 409  
 Famotidine<sup>®</sup>, 75  
 Fatty acids  
     V-enhanced uptake, 148  
 Feldene<sup>®</sup>, 513  
 Fenbufen, 182  
 Fenclofenac, 182  
 Fenton reaction, 172, 180, 247, 262  
 Ferricinium, 193-4  
     heptamolybdate, 194  
     picrate, 194  
     trichloroacetate, 194  
 Ferritin, 162, 181, 263, 269, 558  
 Ferrocene, 180-1, 180, 193-4, 196-7  
     in drug design, 181-5  
     as hydrophobic spacer, 190  
     polyaspartamide conjugates, 194  
     safety, 180  
     as source of cyclopentadienide, 344  
     TMH, 181, 181  
 Ferrocenealdehyde *N*-methyl-*N*- $\beta$ -chloroethyl hydrazone, 193  
 Ferrocenium, 183  
     carboxylic acid hexafluorophosphate, 195  
 Ferrocenyl acridine, 196  
 Ferrocenylacetic acid, 196  
 3-Ferrocenylbutanoic acid, 196  
 4-Ferrocenylbutanoic acid, 195  
 Ferrochloroquine, 185-91  
     analogues, 187  
     enantiomers, 187, 187  
     ferrocene position in, 187  
     racemate, 187  
 Ferrocifens, 183, 184, 185, 196  
 Ferroquine, 185  
 Ferrous sulfate, 179, 181  
 Fever, **444**  
     and As, 298
- Fibrinogen, 70  
 Fibroblastoma, 413  
 Fibrosarcoma, 85  
 Fluconazole, 183, 183  
 Fluorenones, 22  
     boronated, 23  
 9-Fluorenylmethyl carbamate, 347, 348  
 Fluorides, 345  
 Fluorine  
     in organotin carboxylates, 428  
     *p*-Fluoro-hexahydrosiladifenidol, 92, 92  
     2-(4-Fluorophenyl)-1-(1*H*-1,2,4-triazol-1-yl)-3-trimethylsilylpropan-2-ol, 91  
     *p*-Fluorophenylethynylgermatrane, 287  
     *p*-Fluorophenylgermatrane, 287  
     bis(4-Fluorophenyl)methyl(1*H*-1,2,4-triazol-1-yl-methyl)germane, 290  
     bis(4-Fluorophenyl)methyl(1*H*-1,2,4-triazol-1-yl-methyl)silane, 91, 91  
     5-Fluoro-1-(2-tetra-hydrofuryl)-2,4(1*H*,3*H*)-pyrimidinedione, 83  
     5-Fluorouracil, 83, 134, 139, 283-4, 414, **423**, 491  
 Fluorouracil, 502  
 Flurbiprofen, 182  
 Flusilazole, 91, 99, 290  
 Fohn cell line, 409  
 Food and Drug Administration (FDA), USA, 4, 66, 298, 308, 434  
 2-Formyl-2,5-dimethoxy-2,3-dihydro-4*H*-pyran thiosemicarbazones, 228  
 2-Formylpyridine-2'-methyl thiosemicarbazone, 228  
 2-Formylpyridine-4'-methyl thiosemicarbazone, 228  
 2-Formylpyridinethiosemicarbazone, 228, 402  
 Formylpyridyl thiosemicarbazones, 481  
 Fourth International Study of Infarction Survival (ISIS-4), 59  
 Fowler's solution, 297-8  
 Framingham Heart Study, 60  
 Frizzled, 6, 12  
 Frontal cortex, 11  
 Fructose 1  
     6-biphosphatase, 8  
 Ftorafur<sup>®</sup>, 83

Index

- Fungi, 96
  - crop-damaging, 405
  - pathogenic, 403
- Fungicides, 91
  - see also* Drugs, anti-fungal
- 2-Furaldehyde oximes Co complexes, 203
- Furan, 281
  - germyl-trifluoroacetyl derivatives, 288
  - silyl-trifluoroacetyl derivatives, 288
- 3-Furan-2-yl-acrylic acid, 431, 432
- Furfural
  - semicarbazone, 289
  - thiosemicarbazone, 289
- 2-Furfural semicarbazone Co complexes, 203
- Fusarium*
  - lycopersici*, 405
- Futraful, 83
  
- G proteins, 5
- G3G1 cell lines, 414
- Gadolinium, 542, 546–8, 547, 549, 550, 551, 551, 552–4
  - binding to HSA, 548
  - chelates, targeting cells with, 554–9
  - and oxygenation, 552
  - pH dependence of relaxivity, 550
- Gaeumannomyces*
  - graminis*, 91
- Galen, 297
- Gallate, 261–2, 270
- Gallium
  - aqueous biochemistry, 260–1
  - cell uptake, 263
  - chemistry and mechanisms of action, 260–5
  - chloride, 261, 265, 269
  - citrate, 260–2
  - hydroxide, 261–2
  - and iron, 261–3
  - maltolate, 265, 270–1
  - mechanism of action, 264–5
  - nitrate, 261, 264–9
    - citrate, 265–9
    - pharmacokinetics, 268
    - toxicity, 268–9
  - phosphate, 266
  - protoporphyrin IX, 271, 273
  - 8-quinolinolate, 265, 269–70
  - radioisotopes, 260, 263
  - side-effects, 269
  - sulfate, 265
  - tartrate, 259
  - therapeutic compounds, 259–77
  - toxicity, 260
  - transferrin, 265
    - doxorubicin conjugate, 265, 271
- Ganite<sup>®</sup>, 265
- Gastralgine<sup>®</sup>, 70
- Gastric acid, 70, 76
- Gastric mucosa, 73, 336
- Gastritis, 69, 72
- Gastro-oesophageal reflux disease (GERD), 75
- Gastroduodenal ulcers, 72–3
- Gastrointestinal disorders, 530
- Gastrointestinal dysfunction, 174
- Gastrointestinal toxicity, 491
- Gaviscon<sup>®</sup>, 76
- Gd-BOPTA, 542, 543
- Gd-DOTA, 542, 543
- Gd-DTPA, 542–3, 543, 557, 559
- Gd-DTPA-BMA, 542, 543
- Gd-EOB-DTPA, 542, 543
- Gd-HPDO3A, 542, 543, 558, 558
- Gel electrophoresis, 371, 374
- Gel Tin<sup>®</sup>, 433
- Gemcitabine, 502
- Genotoxicity
  - of Sb, 447
- Germadithioacetals, 290
- Germa-flusilazole, 281
- Germanic acid, 280, 287
- Germanium, 85, 279–82, 289
  - biological activity of organo-compounds, 279–95
  - in human tissue, 280
  - modified organic compounds, 288–90
  - optical uses, 280
  - oxide, 280
  - in plants, 280
  - sesquioxanes, 283–4
  - sesquioxide, 283
  - sesquisulfides, 283–4

- Germatranes, 281, 281  
 2-(2-Germaoxa-3H-benzofuran-3-yl)-2-acetylaminoglycine, 284  
 Germathiazolidines, 290  
 Germatranes, 286–8, 286, 290  
   toxicity, 286–7  
 3-(1-Germatranyl)propionic acid, 288  
 1-Germa-2,8,9-trioxa-5-azatricyclo[3.3.3.0<sup>1-5</sup>]undecane, 286  
 Germesquioxanes, 280  
 Germylated sulfides, 290  
 Germylisoxazolin-2-yl, 289  
 Germylporphyrines, 281, 281  
 Gestational hypertension, 53–4  
 Ginseng, 67–8  
 Ginsenocides, 67  
 GLC4 cell lines, 414  
 Glial cells, 11  
 Glioblastoma multiforme, 21  
 Gliomas, 90  
 Glomerulus, 53  
 Glucantime<sup>®</sup>, 444, 445, 445  
 Glucoinositolphospholipids, 454  
 Gluconic acid  
   and Sb, 442, 445  
 Glucopyranosyl, 284  
 Glucosamines, 165  
 Glucose  
   carborane analogue, 36  
   reduced tolerance, 57  
   V-enhanced uptake, 145, 148, 155  
 Glutamine, 160  
 Glutathione, 128–9, 153–4, 383–4, 470, 514–15, 538  
   and As-induced apoptosis, 303–4  
   and Pd complexes, 410  
   peroxidase (GPx), 167, 315, 448  
   photo-induced reduction, 89  
   reduced by PAT, 448  
   reductase, 314  
   reduction of vanadate by, 143  
   structure, 451  
   and Ti drugs, 136  
 Glycine, 24, 138, 480, 515  
   B analogue, 42  
 Glycoconjugates, 454  
 Glycogen synthase kinase-3 (GSK-3), 5–8, 11–13  
   isoforms, 5  
   phosphorylation site, 6  
   signalling pathways, 7  
 Glycosylation, 284  
 Glycosyltransferases, 162  
 Glyoxylic acid, 469  
 Goiter  
   and Li, 15  
 Gold, 139, 155, 346, 388  
   anti-tumor drugs, 517, 520–1  
   carbene complexes, 520  
   in cells, 514–15  
   chemical reactivity, 508  
   cyanide, 510  
   metabolites, 515  
   in medicine, 510–14  
   historical perspective, 510–11  
   metabolism of drugs, 514–15  
   oxidation states and stereochemistries of complexes, 508–10  
   pharmacological potential of complexes, 516–21  
   phosphinegold(I) complexes, 517  
   physical and chemical properties, 507–10  
   potential applications of complexes, 521–4  
   anti-asthma activity, 523  
   anti-HIV/AIDS activity, 524  
   anti-malarial activity, 522–3  
   anti-microbial activity, 521–2  
   tetrahedral complexes, 518  
   thioglucose, 523–4  
   use and potential of metallotherapeutics, 507–27  
 Gonadotropin-releasing hormone, 290  
 Gout, 3  
 Graft rejection, 267  
 Granulomatous reaction, 67  
 Growth factors, 71–3  
 Growth retardation, 239–40  
 GSSG, 153  
 Guanidine triphosphate (GTP), 5  
 Guanine, 127–8, 207, 363, 371–4, 384, 387–8, 495–6, 497

Index

- Guanosine, 404–5  
 Guanosine diphosphate-mannose, 454  
   pyrophosphorylase, 454  
 Guanosine-5'-monophosphate (GMP),  
   370, 372  
 Guinea pigs  
   tuberculosis in, 271  
   urine studies on, 3  
   vaccine tests in, 69  
 Gulose carborane analogue, 36  
 L-Guluronic acid, 76
- H-ras* cell lines, 498  
 H226 cell lines, 423, **423**, **425–30**, 519  
 Haber–Weiss reaction, 172  
*Haemophilus*  
   influenza type b, 69  
 Haemorrhagic stroke, 56  
 Haemoxidase, 433  
 Hal2 protein, 10  
 2-Halogenoethylsilanes, 96  
 Haloperidol, 12  
 Haloperoxidases, 144  
 Hamsters  
   CHO cell line, 404  
   ovary fibroblasts, 211  
   Sb studies in, 447, 449  
 Harmine, 412  
 Health Professionals Follow-Up Study, 119  
 Heart defects  
   and Li, 5  
 Heartburn, 69, 75  
 Heat-shock proteins, 72  
 HeLa cell lines, 288, 304, 404, 407–10, 413,  
   517  
 Helicin-thiosemicarbazone (H-TSC), 223  
*Helicobacter*  
   *pylori*, 72–3, 174, **455**, 530, 535  
 Hematite, 66  
 Heme, 78, 262  
   oxygenase-1 inducers, 203–4  
 Hemoglobin, 262, 269, 552  
 Henle's loop, 52  
 Hep-2 cell lines, 410  
 Hepatic encephalopathy  
   and Mn toxicity, 163  
 Hepatitis C virus (HCV), 446
- Hepatocytes, 262–3, 558  
 Hepatomas  
   ascitic, 283  
   avian, 204  
 Herpes simplex virus, 34, 289  
   1 (HSV-1), 402, 405  
   2 (HSV-2), 405  
 Hetaryl diketones, 288  
 Heteroarylgermatranes, 287  
 1,4,5,8,9,12-Hexaazatriphenylene (HAT),  
   369, 372  
 1,5-Hexadiene, 380  
 Hexahydrosiladifenidol, 92, 92  
 Hexakis-((2-methoxy-2-methyl-1-propyl)  
   isonitrile)Tc(I), 337  
 Hexamethylene, 501  
 Hexamethylpropyleneamineoxime, 336  
 High mobility group (HMG), 493, 497  
 High performance liquid chromatography  
   (HPLC), 207, 346  
 High-affinity folate receptor (hFR), 558  
 Hip abnormalities  
   and Mn deficiency, 162  
 Hippocampus, 11  
 Hippocrates, 297  
 Histamines, 55  
   H<sub>2</sub>-receptors, 70  
 Histidines, 202, 452, 476  
 HIV, *see* Human immunodeficiency  
   virus (HIV)  
 HL-60 cell lines, 410, 412–13  
 HOMO, 369–70, 370  
 HOPO ligands, 546, 547  
 Hormones, 42–4  
   boronated, 43–4  
   calcitropic, 110, 112  
   non-calcitropic, 112  
   steroid, 42–4  
 HOS cell lines, 414  
 Human immunodeficiency virus (HIV),  
   86–7, 169–70, 202, 391, 446, 448  
   and Au drugs, 524  
   and dichlorotin(IV) protoporphyrin,  
     433–4  
   and Pd complexes, 404–5  
   and Se deficiency, 317  
   and Zn, 243–4, 404

- Human serum albumin (HSA), 382  
 Human serum transferrin, 538  
 Hybridoma, 409  
 Hydantoins, 39–40  
     boronated, 40  
 Hydrazines, 472–3  
 Hydrazinonicotinamides, 340, 341  
 Hydrogen peroxide, 161, 164, 171, 196,  
     302, 515  
     and asthma, 316  
     and DNA cleavage, 206  
     and GPX inhibitor, 167  
     and vascular pathology, 168  
 Hydrogermatrane, 287  
 Hydrolases, 160  
 Hydrolytic stability of boronated  
     compounds, 27  
 Hydroperoxides, 322–3  
 Hydrophilicity, 148  
 Hydrotalcite, 71–3, 72  
 Hydroxides, 345  
*N,N'*-bis[2-Hydroxy-3-methoxy-*N*-  
     (pyridyl)-benzylamine]-1,  
     2-phthaldialdimine, 406  
*N,N'*-bis[2-Hydroxy-3-methoxy-*N*-  
     (pyridyl)benzyl-amine]-2,6-  
     diacetylideneperidine, 406  
 tris(3-Hydroxy-2-methyl-4*H*-pyran-4-  
     onato)gallium(III), 270, 271  
 4-Hydroxy- $\alpha$ -methyl-phenyl-2-aminoethyl  
     selenide, 327  
 Hydroxyapatite, 382, 483  
 2-Hydroxybenzothiazole, 388  
 Hydroxycarboxylates, 531–2  
 Hydroxycarboxylic acids, 531, 532  
 9-(2-Hydroxyethoxymethyl)guanine, 502  
 4-(2-Hydroxyethyl)-1-piperazineethane  
     sulphonic acid (HEPES), 195  
 Hydroxyethylidenediphosphonate  
     (HEDP), 482  
 Hydroxy ferrocifen, 184  
 Hydroxygermatranes, 287–8  
 Hydroxylapatite, 266  
 Hydroxymethylsilanes, 92  
 1-(2-Hydroxyphenyl)-2-amino-2-carboxy-  
     ethyl germanium sesquioxane, 284  
 8-Hydroxyquinoline, 214  
*N*-Hydroxysuccinimidylhydrazinonicotin-  
     amide (HYNIC), 341  
 Hydroxytamoxifen, 184–5, 184  
 Hydroxyurea, 502  
 Hyperbilirubinaemia, 433  
 Hypercalcemia, 265, 267–9  
 Hyperglycemia, 169  
 Hyperlipidemia, 77, 167  
 Hyperlipoproteinemias, 77  
 Hyperphosphatemia, 61, 69, 74  
 Hypertension, 4, 77, 80, 116–18, 167  
     arterial, 57  
     in preeclampsia, 118–19  
     in pregnancy, 115, 118–19  
     salt-sensitive, 117–18  
     and Se drugs, 327  
 Hyperzincuria, 244  
 Hypochloridia, 122  
 Hypochlorite, 164  
 Hypochlorous acid, 520  
 Hypocholesterolemia, 162  
 Hypochromia, 269  
 Hypoglycemia, 168  
 Hypomagnesaemia, 58, 60  
 Hypothyroidism  
     and Li, 15  
 Hypovitaminosis, 117  
 Ibuprofen, 15, 513  
 Icterus, 433  
 Ifosfamide, 502  
 IGROV cell lines, 423, 423, 425–30  
 Ilium  
     Mg absorption, 52  
 Imidazo[4,-*f*][1,10]-phenanthroline, 204,  
     205–6  
     bis(Imidazol-2-yl)methylamine, 477  
 Imidazoles, 342, 385  
 Imidazoline, 410  
 Imidazolium, 364  
 Iminoacids, 515  
 Iminodiacetic acid, 477  
 Iminoether, 496–7  
 Impenem<sup>®</sup>, 431  
 Immune system  
     and Zn, 243–4  
 Immunization, 66–7

- Immunoglobulin, 511
- Immunosuppressants
  - Ru, 360
- Impotence
  - and Mn exposure, 163
- Indium<sup>111</sup>, 209
- 1-(3'-Indolyl)-2-amino-2-carboxyethyl-germesquioxane, 284
- Indomethacin<sup>®</sup>, 15
- Infant colic, 70
- Inflammation
  - and Mn, 163
  - respiratory, **444**
  - vaginal, **444**
- Inflammatory bowel disease
  - and Zn deficiency, 241
- Inflammatory pain, 170–1
  - and superoxide, 170
- Influenza, 317
- Inosine, 405
  - monophosphate, 325
- Inositol depletion theory, 11
- Inositol monophosphatase (IMP), 8–9
- Inositol phosphate
  - signalling, 8–10, 9
- Inositol polyphosphatase (IPP), 8–9
- InsP<sub>3</sub>, 8, 8, 9
- Ins(1,4,5)P<sub>3</sub>, 8, 8
- Ins(1,3,4,5)P<sub>4</sub>, 8
- InsP<sub>6</sub>, 8
- Institute of Medicine, Food and Nutrition Board, 241, 251
- Insulin, 13, 148
  - mimetic V-containing compounds, 143–58
  - and Mn deficiency, 161
  - role in glucose metabolism, 144–5
  - resistance, 58
- Insulin-like growth factor (IGF)
  - proteins, 13
- Integrin peptidomimetic antagonist, 555
- Interferon- $\alpha$ , 446
- Interferon- $\gamma$ , 456
- Interleukin-2, 305
- Intravenous magnesium efficacy in stroke (IMAGES) trial, 57
  - magnetic resonance substudy (MR-IMAGES), 57
- Iodine
  - isotopes, 465
  - and Sb, 442
- Iodoacetate, 322
- Iodomethaneboronic esters, 33
- Iodothyronine deiodoninases, 315
- Iron
  - deficiency, 179
  - dextran, 179
  - medical use, 179–200
  - pathway, 153
  - (II) ions, 207
- Ischaemia (stroke), 55–7, 171–2, 338, 551
  - Li therapy in, 14
  - Mg therapy in, 56–7
  - and Mn, 163
- Ischaemic penumbra, 55
- Isodiazene, 473–4
- Isolink kit<sup>®</sup>, 475
- Isonicotinic acid, 381–2
- Isonitriles, 342
- Isoorotic acid, 404
- Isopropylamine, 498
- p*-Isopropylbenzaldehyde thiosemicarbazone, 407
- Isothipendyl (IPH), 405
- Isotopes
  - $\alpha$ -emitting, 464
  - Auger-emitting, 464
  - $\beta$ -emitting, 464–5
  - positron-emitting, 463
  - of Re, 464–5
  - of Tc, 334
- Isoxazoline, 281
- Jaundice, 433
- Jurkat cells, 264, 407
- K562 cell lines, 413–14
- Kainite, 13
- Kaposi's sarcoma, 434
- Karenitecin, 89, 90, 91
- KB cell lines, 411, 413
- Keratinocytes cell line, 407
- Keshan disease, 315
  - and Se deficiency, 316–17
- Ketimines, 406

- Ketoconazole<sup>®</sup>, 523  
 Ketones, 95  
 Kidney, 542  
     As in, 307  
     damage by Li, 15  
     disease and Mg, 61  
     Ga toxicity, 268  
     Li accumulation in, 4  
     Mg excretion by, 52  
 Kidney stones, 121  
     Mg effect on, 61  
 Kinases, 144, 160  
 Kineret<sup>®</sup>, 166  
*Klebsiella*  
     *pneumoniae*, 404  
 Koch, R., 510  
 Krysolgan<sup>®</sup>, 512  
 Kupffer cells, 262–3
- L929 cell lines, 413  
 L1210 cell lines, 283, 410–11, 413–14,  
     422, 519  
 Lactate, 151, 172  
 Lactation  
     and Ca homeostasis, 113  
 Lactic acid, 532, 534  
 Lactoferrin, 263, 538  
 Lanthanides, 542  
 Lanthanum carbonate, 74  
 Larmor frequencies, 545  
 Latitude<sup>®</sup>, 92  
 Lead, 284  
     sulfide, 279  
 Leicester intravenous magnesium  
     interventional trial (LIMIT-2), 58–9  
*Leishmania*, 444–8, 452–5, **455**, 456  
     action and resistance of Sb in, 456  
     amastigotes, 449–50, 454  
     cellular signaling and elimination,  
         455–6  
     *donovani*, 388, 449–50, 453–4  
     *garnhami*, 449  
     *infantum*, 450, 454  
     *mexicana*, 455  
     promastigotes, 449–50, 454  
     purine scavenge pathway,  
         454–5
- Leishmaniasis  
     and Rh complexes, 388  
     and Sb, 441, 444, **444**, 445, 447–8  
 Leprosy, 168  
 Leucine B analogues, 24  
 Leucocytes, 58  
 Leucopenia, 269, 491  
 Leucovorin, 491  
 Leukemia, 264, 271, 290, 364, 381, 422, **455**  
     *see also* Adenocarcinomas; Cancer;  
         Carcinoma; Carcinosarcoma;  
         Lymphomas; Melanoma; Sarcoma  
     acute myeloid (AML), 306  
     acute promyelocytic (APL), 298, 300–2,  
         306, 308  
     chronic lymphocytic (CLL), 299  
     chronic myelogenous (CML), 298, 308  
     and Cu complexes, 224  
     HL-60, 90, 93  
     human myeloid cell line, 407  
     lymphoblastic, 409  
     myelogenous, 222, 413  
     quick-growing, 134  
     and Rh complexes, 380  
 Leukocytes, 263, 515–16  
     radiolabeling, 214  
 Leukocytosis  
     As-induced, 308  
 Leukotrienes, 55  
     B4 inhibition, 323  
 Lewis acid–base reactions, 442  
 Lewis acids, 208  
     Sb, 443  
     Ti(IV), 129–30  
     Zn, 238  
 Librium<sup>®</sup>, 4  
 Lidocaine, 485  
 Limière<sup>®</sup>, 512  
 Linear energy transfer (LET), 19–20,  
     27, 43  
 Lipase, 72  
 Lipid metabolism, 77  
 Lipidol, 469  
 Lipids, 37–8  
 Lipogenesis, 155  
 Lipolysis, 120  
 Lipophilic/hydrophilic balance, 30, 428

Index

- Lipophilicity, 148, 180, 183
- Lipophosphoglycan, 454
- Lipoproteins, 36–7
  - low density (LDLs), 36–7, 37, 44
  - oxidation, 284
  - very low density (VLDL), 78
- Liposomes, 44–5, 552
  - boronated, 45
  - Gd-containing, 554
- Lipoxygenases, 323
- lisA* gene, 9
- Lithia Springs, 2
- Lithicarb<sup>®</sup>, 4
- Lithium, 1–3, 3
  - adverse effects, 14–15
  - biology, 3–5
  - and the body, 4–5
  - carbonate, 2–4
  - chloride, 2
  - citrate, 3
  - and enzyme activity, 2, 10
  - and grey matter, 12
  - hydration shell, 2
  - inorganic chemistry, 2–3
  - ion binding, 2, 5
  - metallotherapeutics, 1–17
  - neuroprotective role, 12–13
  - sedative properties, 3
  - sulfate, 2
  - targets, 5–10
  - therapeutics, 10–15
    - history, 3–4
  - tonic, 3
  - transport, 4–5
  - uses, 1
- Lithotabs<sup>®</sup>, 4
- Liver
  - abnormal enzymes in, 53
  - As in, 307
  - disease
    - and Zn deficiency, 241
- Long QT syndrome, 61
- LoVo cell line, 409
- Luciferase, 204
- LUMO, 370, 370
- Lupine, 169
- Luteinizing hormone suppression, 290
- LX-1 cell lines, 410
- Lymphocytes, 231–2
- Lymphomas, 167, 187, 207
  - see also* Adenocarcinomas; Cancer; Carcinoma; Carcinosarcoma; Leukemia; malignant, 298
  - non-Hodgkin, 267, 285
- Melanoma; Sarcoma
- Lysine, 347–8
- Lytic cocktail, 54
- M19 MEL cell lines, 423, **423**, **425–30**
- Maalox<sup>®</sup>, 70, 73
- Macrophages, 263, 388, 445, 450–1
  - cellular signaling and *Leishmania* elimination, 455–6
- Maghemite, 544
- Magnesium, 3, 160
  - in asthma, 55
  - in the body, 52
  - carbonate, 61
  - cell concentration, 2, 4
  - cellular role, 51
  - cytosolic, 52
  - hydroxide, 73, 75
  - ion binding, 2, 5
  - ionic radius, 2
  - as metallotherapeutic drug, 51–64
  - as mood stabilizer, 62
  - pidolate, 62
  - side effects, 54–5, 59
  - sulfate, 54, 56, 61
  - trisilicate, 70, 75–6
- Magnesium in coronaries (MAGIC) trial, 59–60
- Magnetic resonance imaging (MRI), 57, 554
  - and Fe, 544
  - and Mn, 174, 543–4
  - PARACEST agents in, 548
  - paramagnetic metal complexes as
    - contrast agents for, 541–60, 543
  - responsive agents in, 548–54
    - and enzymes, 552–4
    - and pH, 549–51
    - and redox potential, 551–2
- Magnetite, 66

- Magnevist<sup>®</sup>, 542, 543  
 Maillard reaction, 284  
 Malaria, 185, 190, 192, 522  
     and As, 298  
     and Au, 522–3  
     and Rh complexes, 388  
     and spirogermanium, 286  
     and Zn supplementation, 240  
 Malates, 534  
 Maleonitriledithiolate, 510  
 Malic acid, 138, 532, 532, 534  
 Malinal<sup>®</sup>, 75  
 Malnutrition  
     and Zn deficiency, 241  
 bisMaltolatooxovanadium(IV), 145  
 Mangafodipir, 174, 175  
 Manganese, 334  
     ascorbate, 166  
     chloride, 174  
     deficiency, 161–2  
     diet and water levels, 160  
     environmental prevalence, 159–60  
     ethylene-bis-dithiocarbamate, 159  
     functions, 160  
     future role, 175  
     metallotherapeutics, 159–78  
     3-methoxy-*N,N*-bis(salicylidene)ethylene-  
         diamine chloride (EUK-134), 164,  
         164, 171  
     *N*-nicotinoyl-*N'*-*o*-hydroxythio-  
         benzhydrazide, 167  
     oxide, 159  
     paramagnetic chelates, 543–4,  
         544  
     pentaazamacrocyclic ligand complexes,  
         164, 165  
     related therapeutic agents, 163–5  
     *N,N*-bis(salicylidene)ethylenediamine  
         chloride (EUK-8), 164, 164, 171  
     superoxide dismutase (SOD), 160–1,  
         163–74  
         mimetics, 163–4, 166  
     5,10,15,20-tetrakis-(4-benzoic acid)  
         porphyrin, 173, 173  
     therapeutic uses, 165–74  
     toxicity, 162–3, 168  
 Manganism, 162–3, 174  
 Manic depression  
     and Li, 1  
 Mannitol, 340  
     diuresis, 268  
 D-Mannuronic acid, 76  
 Maple syrup urine disease  
     and Mn deficiency, 162  
 Mastopathies, 96  
 Masurium, 334  
 Matrix-assisted laser desorption  
     ionization mass spectrometry  
     (MALDI MS), 384  
 MCF-7 cell line, 223, 414, 423, 423, 425,  
     425–30, 479  
 MDA-MB 468 cell lines, 410, 412  
 Medulloblastoma, 266  
 Mefloquine, 191  
 Meglumine antimonate, 444, 445, 448–9  
 Melanin, 38  
 Melanoma, 226, 283, 285, 288, 423, 499  
     *see also* Adenocarcinomas; Cancer;  
         Carcinoma; Carcinosarcoma;  
         Leukemia; Lymphomas; Sarcoma  
     B16, 197, 220, 222, 288–9, 380, 517–18  
     choroidal, 391  
     liposome drug-delivery to, 45  
     malignant (melanocyte), 167, 232, 414  
     photokilling, 89  
 Melarsen oxide, 454  
 Melarsoprol, 298  
 Meldrum's acid, 288  
 Meloxicam, 514  
 Meningococci vaccine, 69  
 Mepacrine, 388, 389  
*Mer* configuration, 482  
 Mercaptoacetyltriglycine (MAG<sub>3</sub>), 337,  
     468–9, 472, 474  
 Mercaptoethanol, 471  
 Poly(mercaptoimidazolyl)borate, 478  
 2-Mercapto-3-phenyl-acrylic acid, 432  
 6-Mercaptopurine, 139, 228, 516, 517, 519  
 2-Mercaptopyrimidine, 33, 404, 410  
 Merck index, 532  
 Mercuric chloride, 282  
 Merrifield resins, 347  
 Metabolic diseases  
     and Al, 77–8

Index

- Metal response elements (MRE), 238  
 Metal to ligand charge transfer (MLCT),  
 366–7  
 Metalloporphyrins, 164  
 Metallothioneins, 246, 493, 538  
 synthesis, 243  
 Metastasis, 516  
 Methacrylic acid, 283  
 Methionine, 128, 404, 520, 538  
 Methotrexate, 85, 85, **423**, 514, 516, 517  
 1,1'-bis(Methoxycarbonyl)ferrocene, 480  
 1-(2-Methoxy-phenyl)piperazine  
 cyclopentadienyl, 479–80  
 3-Methoxy-*N,N*-bis(salicylidene)ethylene-  
 diamine chloride (EUK-134)  
 manganese, 164, 164, 171  
 Methyl esters, 409  
*N*-Methyl-D-aspartate (NMDA), 13, 56–7  
 6-Methyl-2-formylpyridine thiosemicar-  
 bazon, 228, 230  
 1-Methyl-4,5-diphenylimidazole, 230  
*N*-Methyl-D-glucamine, 445  
 2-Methyl-5-nitro-1*H*-imidazole-1-ethanol,  
 401  
 3-Methyl-*N*-[(5-nitro-2-furanyl)methy-  
 lene]-4-thiomorpholine-1,1-dioxide,  
 388  
*N*-Methyl-*N'*-nitrosoguanidine, 283  
*S*-Methyl  $N^\beta$ -[(5-nitrothiophene-2-yl)  
 methylene]dithiocarbamate  
 (mndt), 402  
 1-Methyl-4-phenyl-12,3,6,-tetrahydropyri-  
 dine (MPTP), 174  
 (3-Methyl-4-triphenylgermylisoazolinyl-2)-  
 5-carboxylic acid ethyl ester, 289  
 Methylcyclopentadienyl manganese  
 tricarbonyl (MMT), 160  
 bis(Methylcyclopentadienyl)titanocene  
 dichloride, 139  
*S*-Methyldithiocarbamate, 406, 409  
 Methylene bisphosphonates, 33  
 Methylene blue, 193  
 Methylene diphosphonate, 338  
 Methylseleninic acid, 319  
 Methylselenocysteine, 319, 325  
 Methylselenol, 314, 318–20, 325–6  
 Methylsilanetriols, 95  
 Metronidazole, 298, 401–2, 404, 530  
 Mexican bean beetle, 93  
 Mice  
 apoE deficient, 168  
 As studies in, 305  
 athymic, 129, 137  
 Balb/C, 519  
 biodistribution studies in, 468  
 ferrocene treatment, 197  
 fertility and Mn exposure, 163  
 fibroblast studies on DM, 148, 149  
 fibrosarcoma, 167  
 Ga studies in, 259, 266  
 Ge toxicity in, 282  
 hepatoma, 228  
 knockout, 161, 173, 316  
 macrophages in, 283  
 malaria studies in, 185–6  
 melanoma, 226–7, 230  
 Mn studies in, 161, 173  
 neurotoxicity studies, 174  
 paramagnetic studies in, 544  
 radiopharmaceutical studies in, 391  
 Re studies in, 469  
 and Rh complexes, 381  
 Sb studies in, 447  
 Se studies in, 316–17  
 Swiss, 269, 481  
 toxicity studies in, 174, 392  
 vaccine tests in, 69  
 white mongrel, 227  
 xenografts in, 134  
*Microcus*, 404  
 Microcytosis, 269  
 Microtubule associated protein 1B  
 (MAP1B), 7  
 Microtubules, 7–8  
 Migraine  
 and Mg, 62  
*Miliaria crystallina*, 162  
 Miraluma<sup>®</sup>, 338  
 Miravant Medical Technologies, USA,  
 434  
 Mitochondrial membrane  
 collapse of potential, 303  
 Mitogen-activated protein kinase  
 (MAPK), 166

- Mitomycine C, 412, 414  
 Mitotic indices, 231–2  
<sup>99</sup>Mo/<sup>99m</sup>Tc generator, 334–5  
 Mobic<sup>®</sup>, 514  
*Molinema dessetae*, 389  
 Molybdates, 335  
 Molybdenum, 136, 334, 350  
     <sup>99</sup>Mo isotope, 334–5  
 Monoamine monoamide, 339–40  
 Monoblastic cell line, 407  
 Monocytes, 263  
 Monomethylarsonic acid (MMA), **299**,  
     300, 306  
 Mood disorders, 4  
     and PO activity, 9  
 Morbidity, foetal and maternal, 53  
 MORFs radiolabelling, 469  
 Morpholine, 409  
 Mortality, foetal and maternal, 53  
 Motor neuron disease, 174  
 Moulds, 537  
 MRE-binding transcription factor-1, 238  
 MTI-800, 93  
 Multihance<sup>®</sup>, 542, 543  
 Multiple inositol polyphosphate  
     phosphatase (MIPP), 9, 9  
 Multiple sclerosis  
     and Mn deficiency, 162  
 Muscarinic antagonists, 92  
 Muscle contraction, 109  
 Mychrisis<sup>®</sup>, 511  
*Mycobacterium*, 264  
 Myelodysplastic syndrome (MDS), 309  
 Myeloid cells, 263  
 Myeloma, 267  
     multiple, 299, 308–9  
 Myeloperoxidase, 515, 520  
 Myelosuppression, 298, 491  
 Mylanta<sup>®</sup>, 70  
 Myo-inositol, 8, 8  
     hexaphosphate, 241  
 Myocardial infarction, 338  
 Myocardial perfusion, 338  
 Myochrisin<sup>®</sup>, 511  
 Myocytes, 60  
 Myochrisin<sup>®</sup>, 511  
 Myocrisin<sup>®</sup>, 511  
 Myoview<sup>®</sup>, 337  
 Mytomycine, 502  
 NADH, 144, 154  
 Naprosyn<sup>®</sup>, 513  
 Naproxen, 15, 513  
 1,2-Napthaquinone, 223, **223**  
 National Cancer Institute (NCI),  
     USA, 422  
 National Health and Nutrition  
     Examination Survey (NHANES),  
         117  
         third survey (NHANES III), 119–20  
 National Heart, Lung and Blood Institute  
     (NHLBI) asthma guidelines, 55  
 Nausea, 73  
     from Li, 14  
 Nedaplatin, 490  
     anti-tumor activity, 490–1  
     mechanism of action, 494–5  
*N*-Neopentyl-*N*-nitrosourea, 290  
 Nephrotoxicity, 380–1, 407, 491  
     of Au, 513  
 Nerve growth factor (NGF), 13  
 Netropsin, 501  
 Neuralgia  
     and As, 298  
 Neuroblastoma, 299  
 Neurofibrillary tangles, 12  
 Neurolite<sup>®</sup>, 336–7  
 Neurotoxicity, 286, 491  
 Neutrophils, 55, 263  
 Nickel, 399–400, 508  
     chloride, 405  
 Nicotinamide Adenine Dinucleotide  
     Phosphate (NADPH), 433, 451  
     oxidase, 168  
 Nifurtimox, 388  
 NIH Consensus Conference, 113–14  
 Niobium, 136  
 Niridazole, 388  
 Nitric oxide, 58, 161, 164, 456  
     and hypertension, 167–8  
     and superoxide, 321  
     and V action, 155  
 Nitrides, 466, 472  
 Nitrido-complexes, 472–3

Index

- Nitrogen, 441, 509
  - mustards, 211–13
- Nitroimidazoles, 38
  - boronated, 38
- p*-Nitrophenoxy, 136
- 2-Nitro-*N*-(phenylmethyl)-1*H*-imidazole-1-acetamide, 388
- bis(Nitrophenyl)phosphate (BNPP), 208–9
- Nitrosyls, 360
- 1-(5-Nitrothiazol-2-yl)-2-imidazolidinone, 388
- Nociceptive pathway, 171
- Non-steroidal anti-inflammatory drugs (NSAIDs), 182, 513
  - damage by, 530
  - and Li toxicity, 15
- Noradrenalin, 327
- Norbornadiene (NBD), 380–1
- 19-Nortestosterone, 85
- Notch processing, 12
- Novo-chloroquine<sup>®</sup>, 514
- Nuclear magnetic resonance (NMR) spectroscopy, 207, 422, 424, 452, 531, 538
- Nucleic acids, 19, 129
  - B-containing precursors, 27–31, 28
- Nucleosides, 19, 86, 133, 392
  - B-containing, 22, 28, 28–30, 30
  - applications, 42
  - derivatives, 43
  - hydrophilically enhanced, 31
  - silylated, 86
- Nucleotides, 19, 392
  - B-containing, 22, 30, 32
  - applications, 42
  - excision repair, (NER), 493–4, 497
- Nystatine, 87–8
  
- Obesity, 57
- Octreotide, 343–4, 474
- Ofloxacin, 74
- Oligonucleotides, 371
  - antisense agents, 40–2
  - bonding to DNA, 41
  - bonding to RNA, 41
  - boronated, applications, 42
  - dinucleotide analogues, 41
  - specific targeting by, 373, 375
- Oligopeptides, 144, 343
- Oligosiloxanes, 94
- Oliguria, 53–4
- Olomoucine, 414
- Omeprazole, 530
- Omniscan<sup>®</sup>, 542, 543
- Organoiron
  - as anti-cancer agent, 193–8
- Organopalladates, 410–11
- Organosilicons
  - biological activity, 83–107
  - modification, 84–92
  - preparation, 84
  - specific compounds, 94–6
- Organotin, *see* Tin
- Orgotein<sup>®</sup>, 163
- Orpiment, 297
- Orthopalladates, 407
- Oscillo-polarography, 531
- Osmolarity
  - and Li, 2
- Osteoarthritis, 165–6
- Osteoclasts, 284
- Osteodystrophy, 74
- Osteomalacias, 79
- Osteoporosis, 115–16, 171–2, 284
  - Mg supplementation in, 61
  - and Mn, 163
  - and Mn deficiency, 162
- Ototoxicity, 491
- Oxalates, 151, 467
- Oxalilplatin, 413, 490
  - anti-tumor activity, 490–1
  - mechanism of action, 494–5
- Oxalyl homocysteine thiolactone, 385
- Oxidative stress, 447
- Oxides, metal, 66
- Oxovanadium, 143
- Oxygen, 161
  - reduced partial pressure ( $PO_2$ ), 551–2
- N*-Oxysuccinimidylhydrazinonicotinamide (HYNIC), 474
  
- p53, 13–14, 166, 247–8, 304–5, 499
- P388 cell lines, 413–14, 422, 517

- Paclitaxel, 502  
 Paget's disease, 34, 267–8, 270  
 Paired helical filaments (PHF), 8  
 Palladium, 359, 508  
   acetate, 407  
   chloride, 405  
   complexes  
     amine, 412–14  
     anti-fungal activity, 400–7  
     anti-microbial activity, 400–7  
     anti-tumor activity, 407–14  
     anti-viral activity, 400–7  
     compared to Pt, 414–15  
     of drugs used as ligands, 404–5  
     nitrogen and other donors, 410–14  
     with Schiff base ligands, 405–6  
     and sulfur-donor ligands, 400–4,  
       407–10  
     use in medicine, 399–419  
   (diethyl- $\alpha$ -benzeneazobenzene-*N*-benzyl-  
   phosphonate)<sub>2</sub>Cl<sub>2</sub>, 411  
   halide, 411  
 Pam-ras cell line, 407, 409  
 Pamidronate, 267  
 Panax  
   *ginseng C.A. Meyer-root*, 67  
 Pancreas, 262  
 Paracelsus, 297  
 Paramagnetism, 207  
   contrast agents in, 541–4, 543  
   metal complexes in MRI, 541–60  
   determinants of relaxivity, 544–8  
 Parasites, 264, **455**  
 Parathyroid hormone (PTH), 112, 117  
 Paratryl-phenolate (ptp), 228  
 Parenteral nutrition  
   and Mn deficiency, 162, 172  
   and Zn deficiency, 239  
 Parkinson's disease, 340  
   and Al toxicity, 79  
   and Se deficiency, 315  
 Patronite, 143  
 Pauling scale, 508  
 PCP2A, 546, 547  
 Pea aphid, 93  
 Pellagra  
   and As, 298  
 Penciclovir, 405  
 Penicillamine, 252  
 Penicillins, 298  
   ferrocene-containing, 182  
*Penicillium*  
   *camembertii*, 537  
   *citrinum*, 522  
 Penta-ammineruthenium complexes, 362  
 Pentafluorothiophenolate (pftp), 228  
 Pentaminecobalt(III), 202  
 Pentaquine, 388, 389  
 Pentostam<sup>®</sup>, **444**, 445, 445, 456  
 Pepsin, 70  
 Peptic ulcers, 69–73  
 Peptides  
   B-containing, 24–7, 27  
   BIV trans-activating, 392  
   Co-containing, 202, 202  
   gastrin-releasing, 471  
   Re tagging, 348–9  
   and Re chelates, 478  
   and Sb, 449  
   Tc tagging, 340, 347–8  
   Zn finger, 202  
 Pepto-Bismol<sup>®</sup>, 530–1  
 Periodontal disease, 120–1  
 Peripheral blood mononuclear (PBM)  
   cells, 446  
 Peritoneal adhesions, 172  
   and Mn, 163  
 Permeability transition pore complex  
   (PTPC), 303  
 Peroxidases, 161  
 Peroxovanadates(V), 144  
 Peroxynitrites, 161, 167–8, 321, 327  
 Perrhenate, 467, 469, 471, 473–5, 477, 482  
 Pertechnetate, 475  
 Perthes' disease  
   and Mn deficiency, 162  
 Peyrone's chloride, 489  
 pH  
   dependence of relaxivity, 552  
   sensitive contrast agents, 549–51  
   V complexes and, 149–52, 150–1  
 Phaeophyceae, 75  
 Phagocytes, 456  
 Phagocytosis, 556

## Index

- Phenamine, 288
- Phenanthrenequinone diimine ( $\phi$ ), 387, 387
- Phenanthridinium, 388
- B-containing analogues, 24, 24
- 1,10-Phenanthroline, 138, 232, 380, 382, 387, 387, 532
- 1,10-Phenanthroline-2,9-dicarboxaldehyde, 405
- Phenolics, 144
- Phenothiazine, 39
- Phenylaminoethylselenides, 327
- 2-Phenyl-1,2-benzisoselesazol-3(2H)-one, 321
- o*-Phenylenediamine, 405
- Phenylgermatrane, 287
- Phenylketonuria
- and Mn deficiency, 162
- Phenylselenenyl-1-naphthol, 323
- Phenylsulfones, 22
- Phenytoin, 13, 54
- Phosphatases, 144, 238, 266
- Phosphates, 31–3, 144, 151
- binders, 73–5
- deficiency, 75
- pathway, 153
- Phosphinegold(I)
- chloroquine complex, 522
- thiolates, 517, 519
- Phosphineoxides, 518
- Phosphines, 342, 466–8, 471, 509, 513, 515, 518
- 3'-Phosphoadenosine 5'-phosphate PAP phosphatase (RnPIP), 8, 10
- Phosphoenolpyruvate decarboxylase, 160
- Phosphoisomerases, 144
- Phospholipids, 37–8
- carborane-containing, 37
- Phosphomonoesterase (PME), 5
- Phosphomutases, 144
- Phosphonates, 31–3
- Phosphonic acids, 411
- Phosphonoacetic acid
- anti-viral activity, 34
- Phosphonoformic acid
- anti-viral activity, 34
- Phosphoramidates, 31–3
- Phosphorus, 85, 112, 441, 509
- and Sb, 442
- Phosphorylation, 6, 145, 153, 155
- Phosphotyrosine phosphatases (PTPase), 145
- Photoadduct formation
- by photoelectron transfer, 371–2, 372
- Photodynamic therapy (PDT), 367, 434
- Photoelectron transfer
- and DNA cleavage, 368–71
- Photoreactivity
- of polyaaromatic Ru complexes, 365–72
- Photosensitizers, 366–8
- Phototherapy, 365–6
- Phytate, 241
- PI3 kinase, 13
- Picolinic acid, 148
- Pigment inhibition, 390
- Pilocarpine, 11
- Pinocytosis, 195, 555–6
- Piperazine, 496–8
- Piperidine, 380, 409, 496–8
- PIP<sub>2</sub>, 8
- Piroxicam, 513
- Pitchblende, 334
- Plaque, 484
- Plasmocytoma, 410
- Plasmaquine, 388, 389
- Plasmid bluescript KS, 231, 231
- Plasmodium*, 185
- berghei*, 522
- falciparum*, 78, 186, 188, 190, 192, 272, 522
- vinckeii*, 186
- Plastocytoma, 519
- Platelet activation
- Mg in, 58
- Platinum, 155, 326, 359, 392–3, 399–400, 508
- anti-viral drugs, 501–2
- blues, 385
- combination with other agents, 502
- complexes, compared to Pd, 414–15
- drugs, 489–506
- JM216, 499, 500
- JM335, 499–500, 500



Index

- specificity 1, 238
- synthesis, 41
- Tc tagging, 340
- Zn finger, 247
- Proteinuria, 53, 118, 268
- Proteoglycans, 165–6, 172
- Proteophosphoglycan, 454
- Proteus mirabilis*, 535
- Proxigermanium, 280, 282
- Pseudomonas*, 404
  - aeruginosa*, 402, 521–2, 535
- Psoriasis
  - and Li, 15
  - and Mn, 163
- Pulmonary edema, 53
- Purines, 27, 86, 325, 361, 392, 492, 498
  - B-containing, 22
  - scavenge pathway in protozoan parasites, 454–5
- Putrescine, 34–5, 412, 412
- Pyrazole
  - Rh complexes, 386
- Pyrethroids, 93
- Pyridine-2-carbaldehyde thiosemicarbazone, 402
- Pyridines, 342
- Pyridinesulfonate, 369
- Pyridinone, 145, 151
- Pyridoxal isonicotinoyl hydrazone (PIH), 271, 272
- Pyridyl-2-carbox-midrazone, 226
- Pyridylhydrazine dihydrochloride, 474
- Pyrimidines, 27, 86, 387, 498
  - B-containing, 22
  - nucleosides, 31
- Pyrolusite, 159
- Pyrone, 145
- Pyrophosphates
  - B analogues, 33–4, 34
  - synthesis, 34
- 3-Pyrrolyl-2,5-dihydro-1H-2,5-pyrroledione, 88
  
- QT intervals
  - and As, 308
- Quilonum SR<sup>®</sup>, 4
- Quinines, 55, 191
  
- Quinol oxidase, 272
- Quinoline, 496–7
- tris(8-Quinolinolato)gallium(III), 269
- Quinolone, 252
- 2-Quinolylmethylphosphonate, 413
  
- Rabbits
  - hypercholesterolemic, 284
- Radiation
  - sensitizers, 38
  - therapy, and SOD isoforms, 163
- Radiodiagnostic imaging
  - Ru in, 360
- Radioisotopes, 463–4
- Radionuclides, 333, 464
- Radiopharmaceuticals, 336–44, 463–4
- Radiotherapy, 502
- Radiotracers, 336, 340
- Ranitidine, 75, 530
  - Bi citrate, 530, 531
  - hydrochloride, 530
- Rats
  - antiparasitic studies in, 388
  - arthritis studies in, 166
  - As studies in, 306
  - Au studies in, 520
  - carcinosarcoma studies in, 137
  - DM studies in, 145, 148, 150, 155, 168
  - Ga studies in, 265–6, 268–9
  - Ge toxicity in, 282
  - glycogen synthesis in, 6
  - hypertension studies in, 167
  - Istar, 485
  - Li rearing studies in, 11
  - Mn epilepsy studies in, 169
  - Rh studies in, 385, 388, 391
  - Sb studies in, 447
  - Se studies in, 326
  - stomach lesions, 283
  - ulceration model, 537
  - Wistar, 388
  - Zn deficiency in, 246
- Re-entrant supraventricular tachycardia, 61
- Reactive oxygen species (ROS), 246–7, 302–4, 321, 456
- Realgar, 297–8

- Recombinant anthrax vaccine, 68  
 Recommended dietary allowance (RDA)  
     for Zn, 241–2  
 Recommended nutrient intake (RNI)  
     for Zn, 241–2  
 Reflux oesophagitis, 69  
 Relaxivity, 544–8  
     pH dependence, 550  
 Renal disease/failure, 73–4, 80  
 Repargermanium, 280  
 Reperfusion, 171  
     and Mn, 163  
 Resovist<sup>®</sup>, 544  
 Respiratory burst, 456  
 Restenosis, 168, 484  
 Retinobenzoic acid, 92, 93, 290  
 Retinoic acid, 93, 238, 301  
     all *trans* (ATRA), 298, 301–2, 308  
     receptor alpha (*RARα*) gene, 301  
     syndrome, 308  
 Reverse transcriptase, 169  
 Rexagermanium, 280  
 Rhabdomyosarcoma, 385  
 Rhenium, 336, 348–9, 351  
     aminethiolate complexes, 469–70  
     β-emitting isotopes of  
         <sup>186</sup>Re, 464–5, 464, 471, 480–1  
         <sup>188</sup>Re, 464–5, 464, 471, 480–1  
     compared to Tc, 466–7  
     diazenide and isodiazene derivatives,  
         473–4  
     dioxo complexes, 471  
     diphosphonate complexes, 482  
     direct labelling, 471–2  
     first-generation agents, 482–5  
         bone-targeting phosphonate  
             complexes, 482–3  
         for endovascular radiation therapy,  
             484–5  
         for radiation synovectomy, 485  
         [Re(V)-oxo(DMSA)], 483–4  
     and MAG<sub>3</sub> type ligands, 468–9  
     nitride, 473  
     nitrido-complexes, 472–3  
     radiopharmaceutical chemistry, 467–82  
         complexes with metal–N multiple  
             bonds, 472–4  
         complexes with oxo-cores, 467–72  
         complexes of the Re(I) tricarbonyl  
             core, 474–9  
         miscellaneous approaches, 480–2  
         organometallic approaches, 479–80  
         steroid modelling, 472  
         therapeutic radiopharmaceuticals,  
             463–87  
             synthetic aspects, 466–7  
         thiosemicarbazone complexes, 469  
         tin colloid, 485  
         tricarbonyl, 480  
             cyclopentadienyl conjugates, 479  
 Rheumatism  
     and As, 298  
 Rheumatoid arthritis, 165–6, 270, 485,  
     510–11  
     *see also* Arthritis  
     Au therapy for, 511–14  
 Rheumatrex<sup>®</sup>, 514  
 Rhodium  
     anti-bacterial activity, 388–90  
     anti-parasitic activity, 388–90  
     complexes  
         acetato, 382, 383–4  
         activity of phosphine ligand, 382  
         anti-metastatic effect, 380  
         anti-tumor activity, 379–88  
         binuclear, 383, 389  
         dirhodium(II), 383–4  
         ditolylformamidinato, 383  
         mutagenicity, 393  
         polynuclear, 385  
         Rh(I), 380–1  
         Rh(II), 381–5, 381  
         Rh(III), 385–8  
         Rh(III) octahedral, 384  
         similarity to Pt complexes, 379–80  
         toxicity, 392–4  
     in medicine, 379–97  
     photochemotherapy, 391–2  
     radiatorhodium agents, 390–1  
     trichloride, 391–3  
     (II) acetate, 382  
     (II) carboxylates, 382–3, 392  
     (II) citrate, 381–2  
     (II) glucuronate, 381–2

Index

- (II) ketogluconate, 381–2
- (II) trifluoroacetate, 382
- wires, 384–5
- Rhodococcus equi*, 271
- Ribonucleotide, 264
  - reductase, 223, 264
- Rice blast, 91
- Rice sheath blight, 91
- Ridaura<sup>®</sup>, 512
- Rifamycins
  - ferrocene-containing, 182
- Riopan<sup>®</sup>, 70
- Riperfusion, 58–9
- RNA
  - inhibition, 361, 383, 493
  - messenger, 203
  - polymerases, 238, 385, 493–4
  - suppression, 286
- Rodenticides, 94
- Roloids<sup>®</sup>, 70
- Rotterdam Cancer Institute, Netherlands, 423
- Ruthenium, 204, 388
  - in cancer therapy, 359–78
  - chloro-ammino derivatives, 361–2, 362
  - complexes mimicking Pt drugs, 360–5
  - dimethyl-sulfoxide complexes, 362–4, 363
  - mixed chloride/heterocyclic ligand complexes, 364–5, 365
  - NAMI complexes, 364
  - 2,3-naphthalocyanine, 368, 369
  - photo-cleavage of DNA, 367
  - photo-oxidizing complexes, 369
  - photoadduct formation, 371–2
  - photoreactive polyazaaromatic complexes, 365–72, 373–4
  - polypyridyl complexes, 366–7, 368
  - targeting base residues of specific sequences, 373–5
- Saccharomyces cerevisiae*, 10
- Salens, 164
  - protective effects of Mn, 164, 166, 171
- Salicylaldehyde thiosemicarbazone, 223, 224
- Salicylates, 514, 534
- Salicylic acid, 531, 532
- Salivary glands, 336
- Salmonella typhimurium*, 392
- Salvarsan (606), 298
- Sandoz, 89, 90
- Sanochrisin<sup>®</sup>, 512
- Sanocrysin<sup>®</sup>, 512
- Saponins, 68
- Sarcoma, 233, 288, 385
  - see also Adenocarcinomas; Cancer; Carcinoma; Carcinosarcoma; Leukemia; Lymphomas; Melanoma
  - 180 cell lines, 413
  - ascitic, 380
  - astrogenic, 414
  - Guerin T8, 382
  - Kaposi's, 434
  - osteogenic, 220, 266
  - Yoshida ascites, 382
- Saturated calomel electrode, 370
- Schiff base, 78, 409
  - complexes
    - of Co, 202
    - of Pd(II), 405, 409
- Schizophrenia
  - Li therapy in, 4, 10–12
- Se-allyl-DL-selenocysteine, 326
- L-Se-methylselenocysteine, 319
- Sea urchins
  - Li studies in, 5
- Seizures, 53
- Selenates, 313, 509
- 1,3-Selenazine, 325, 328
- Selenazofurin, 325, 327
- Selenides, 313–15, 413
- Seleninic acid, 322, 324
- Selenites, 313–15
- Selenium, 249, 313, 509
  - anti-bacterial, 328
  - anti-cancer, 324–6
  - anti-viral, 327
  - biochemistry, 313–15
  - and cancer prevention, 317–21
  - deficiency-associated diseases, 315–17
  - DNA repair by, 320
  - inhibition of TrxR, 320–1

- Selenium (*Continued*)  
 interaction with As, 317–18  
 medical use in drugs, 313–32  
 metabolism, 314  
 metabolites, 319–20  
 synthetic therapeutics, 321–8  
 therapeutic uses of supranutritional  
 doses, 317–21  
 toxicity, 313
- Selenium and Vitamin E Cancer  
 Prevention Trial (SELECT), 249
- Seleno-bis(S-glutathionyl) arsinium,  
 317
- Selenocyanates, 324, 326
- Selenocysteine, 314, 325  
 conjugates, 325–6, 326
- Selenols, 319–20, 322, 326
- Selenomethionine, 315–16, 318–19
- Selenoproteins, 315, 318
- Selenosis, 313–14
- Semi aquo ion, 476
- Seminiferous tubules, 262
- Senile plaques, 12
- Sepsis risk, 166
- Serine, 5  
 protease inhibitors, 202
- Serocion<sup>®</sup>, 280
- 7 UP, 3
- Sharp eyespot, 91
- Shiosol<sup>®</sup>, 511
- Shock, endotoxic, 267
- Short bowel syndrome  
 and Zn deficiency, 241
- Sickle cell anemia, 62  
 and Zn deficiency, 241
- Side effects  
 of chrysotherapy, 513  
 of cisplatin, 490  
 drug-related, 138  
 of Ga, 269  
 of Sb, 447  
 of Zn deficiency, 239
- Sila analogues, 92–3
- Silabolin<sup>®</sup>, 85, 85
- Silafluofen, 93, 93
- Silanedioles, 95
- Silanetriols, 96
- Silanols, 92, 95
- Silatecans, 89–91
- Silatranes, 94, 94  
 low toxicity, properties, 94
- 3'-O-Silatranylthymidine, 86, 86
- Silica, 66
- Silicon, 94, 279–80, 289, 406  
 naphthalocyanines, 88, 88  
 phthalocyanines, 88, 88, 89  
 tetradibenzobarrelenophthalocyanines,  
 88
- Silicones, 94–5
- Siliperisone, 89, 90
- Silthiopham, 91, 91
- Silver, 51, 508, 518
- Silyl method, 83
- Silylation, 83  
 C-, 89–92  
 O-, S- and N-, 84–9
- Silylcampthothecins, 89
- Simeconazole, 91, 91
- Simethicone, 70, 94
- Single photon emission computed  
 tomography (SPECT), 338–9, 349,  
 351, 554
- Sister Chromatid Exchange (SCE), 231–2,  
 447
- Skin disorders  
 and As, 298
- Sleeping sickness, 433, 454, **455**
- Sodium, **3**, 510  
 antimony(III) gluconate, 445  
 arsenite, 204, 307  
 bicarbonate, 76  
 borohydride, 342  
 carbonate, 530  
 ferric gluconate, 179  
 gold 4-amino-2-mercaptobenzoic acid,  
 512, 512  
 hydration shell, 2  
 penicillin, 405  
 selenite, 315–16, 318–19  
 stibogluconate, **444**, 445–50, 453  
 bis[2-(3',6',9'-trioxadecyl)-1,2-dicarba-  
 closo-dodecaborane-1-carboxylato]  
 triphenylstannate, 432  
 valproate, 252

Index

- Solar keratoses, 434
- Solganol<sup>®</sup>, 511
- Solid-phase synthesis (SPS), 347–8
- Somastatin, 468
- Spectroscopy
  - inductively coupled plasma (ICP), 136
  - NMR, 343, 371–2
- Spermidine, 34–5, 412, 412
- Spermine, 34–5, 412, 412
- Sphalerite, 259
- Spirogermanium, 281, 281, 285–6, 285
- Spodumene, 2
- Spray-freeze-drying (SFD), 67
- Stannous chloride, 335–6, 338, 467, 471
- Stannous tartrate, 481
- Staphylococcus*, 390
  - aureus*, 88, 168, 328, 389–90, 402, 405, 521
- Steroids
  - B-containing, 44
  - modelling, 472
- Stibnite, 441
- Stibophen<sup>®</sup>, 445
- Stigmasterol, 133
- Streptomyces verticillus*, 206
- Streptonigrin, 521, 521
- Stroke, *see* Ischaemia (stroke)
- Structure-activity studies, 495–8
- Succinate, 172
- Sucalfate<sup>®</sup>, 70–1
- Sucrose, 70
- Suicide, 1, 4, 14
- Sulfadiazine, 381–2
- Sulfaquinoxaline, 385
- Sulfate pathway, 153
- Sulfonamides, 145
- Sulfones, 22
- Sulphonylureas, 145
- Sulfur, 313–14, 327–8, 400, 493, 509
  - and Pd complexes, 400–4
- Sulphydryl-shuttle, 514–15
- Superoxides, 164, 167–8
- Suramin, 446
- Synovectomy, 485
- Synthetase, 160
- Syphilis, 168, 259, 444, 510
  - and As, 298
  - and Bi, 529
- Systemic lupus erythematosus, 444, 511
- T-cell
  - activation, 266
  - factor transcription factors (TCFs), 6
  - leukemic cell line, 407
- T-helper cells
  - type 1, 266
  - type 2, 66, 266
- T-lymphocytes, 283
- Talcid<sup>®</sup>, 71–2
- Tamoxifen, 183, 184, 185, 479
- Tartar emetic<sup>®</sup>, 444, 444
- Tartaric acid, 532, 534
  - and Sb, 442, 444
- Tartrates, 534
- Tau, 7, 12
- Tauredon<sup>®</sup>, 511
- Taxol, 209
- Tc-isonitrile, 338, 341
- Tc-Sestamibi, 337, 337, 338
  - [<sup>99m</sup>TcO] apcitide, 343
  - <sup>99m</sup>Tc-teboroxime, 337, 337
  - <sup>99m</sup>Tc-TRODAT-1, 340, 340
- Technetium, 465–6, 475, 479
  - chelate complexes, 337
  - compared to Re, 466–7
  - current research, 344–50
    - bioorganometallic chemistry, 344–5
    - <sup>94m</sup>Tc, 349–50
    - solid supports, 345–9
  - historical account, 334–6
  - ‘instant kits’, 335
  - isonitrile, 337–8
  - isotopes, 334
    - <sup>86m</sup>Tc, 334
    - <sup>93m</sup>Tc, 334
    - <sup>94</sup>Tc, 334
    - <sup>97</sup>Tc, 334
    - <sup>98</sup>Tc, 334
    - <sup>99m</sup>Tc, 333–5, 337, 463, 465, 468, 471, 473–4
    - <sup>99</sup>Tc, 334–6
  - in medicine, 333–58

- Technetium (*Continued*)  
 nuclear properties, 334–6  
 pentavalent technetium-99<sup>m</sup>-DMSA, 483  
 peptide conjugates, 343  
 radiopharmaceuticals, 336–43, 350–1  
   essential compounds, 336–8  
   peptide-targeted, 343–4  
   tagged compounds, 338–43  
 teboroxime, 337
- Tegafur, 83
- Tellurides, 413
- Telomerase inhibitors, 22
- TentaGel, 346
- Teratogens  
 Li as, 5
- Teslascan<sup>®</sup>, 174, 175
- Testosterone, 133  
 suppression, 290
- Tetanus, 80  
 (2,3,4,6-Tetra-*O*-acetyl-1-thio- $\beta$ -D-glucopyranosyl)(triethylphosphine) gold(I), 512, 512
- 1,4,7,10-Tetraazacyclododecane (cyclen), 208, 208
- 1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA), 469
- 1,4,7,10-Tetraazacyclododecane-*N,N',N'',N'''*-tetrakis-methylenephosphonic acid, 552
- bis-Tetraazamacrocyclo-xylyl-bicyclan, 404
- 1,4,5,8-Tetraazaphenanthrene (TAP), 369, 371–2, 374
- Tetrabutylammonium chloride, 475
- Teratocarcinoma, 90
- Tetrachlorogermane, 280
- Tetracycline, 252
- Tetradentate Tc(V), 340
- Tetraethylgermane, 280
- Tetrahalogenides, 130
- Tetrahydrofuran, 475
- Tetrakis(isonitrile)Cu(I), 338
- N,N,N',N'*-Tetrakis(2-pyridylmethyl) ethylenediamine (TPEN), 248
- Tetraorganodicarboxylatodistannoxanes, 424, 424
- 1,5,9,13-Tetrathiacyclo-hexadecane-3,11-diol (*L'*), 391
- Tetrathiacyclohexadecanes, 391
- 2,5,8,11-Tetrathiadodecane-1,12-dicarboxylic acid, 391
- Therapy  
 anti-retroviral, 170  
 combination, 167
- Thermolysin, 202
- Thiabendazole (TBZH), 232, 232
- Thiazole, 388, 496–7
- Thiazolo-2,4-pentanedione, 405
- 2-(4'-Thiazolyl)benzimidazole, 232
- 2-Thienylgermatrane, 287
- 2-Thienylmethyl-germatrane, 287
- p*-(2-Thienyl)phenylgermatrane, 287
- Thioacetamide, 385
- Thiobis[ethylenenitrilo(tetra-acetic acid)], 391
- Thioethers, 342, 509
- Thioguanine, 138  
 L = 6-Thioguanine, 139
- Thioisoorotic acid, 404
- Thiol-shuttle, 514–15
- Thiolates, 452, 467, 509, 511, 536
- Thiols, 346, 500, 522  
 facile exchange, 514
- Thiomorpholine, 409
- Thiones, 431
- Thiophene, 281
- Thioredoxin, 322  
 reductase (TrxR), 314  
 inhibition by Se, 320–1
- Thiosemicarbazides, 406, 469
- Thiosemicarbazones, 223
- Thiosemicarbazones, 228, 400–2, 401, 407–9, 481–2  
 Co complexes, 203
- bis(Thiosemicarbazones) (bTSC), 220, 220
- Thiouracils, 39  
 boronated, 45
- Thioureas, 342  
 boronated, 39  
 cyclic derivatives, 38–9
- Thiovanadates, 143
- Thiuramdisulfides, 409
- 3T3 cell line, 409

- Threonine, 5  
 Thrombin, 202  
 Thrombocytopenia, 53, 491  
 Thromboxanes, 58  
 Thrombus formation  
     and Mg, 58  
 Thymidine, 133, 228  
 Thymidylate synthetase, 203  
 Thymine, 86  
 Thyroid, 336  
 Tin, 139, 279, 406, 421, 433–5, 467  
     *see also* Stannous compounds  
     chloride, 480  
     dichlorotin(IV) protoporphyrin,  
         433–4, 434  
     diorganotin compounds  
         dihalides, 424  
         thiolates, 433  
     ethyl etiopurpurin, 434–5, 434  
     fluoride, 433  
     organotin compounds, 421–2, 427  
         anti-tumor pre-screening, 422–3, 427  
         B-containing, 428–9  
         cytotoxicity testing of carboxylates,  
             423–5  
         di-*n*-butyltin compounds, 424  
             carboplatin analogue, 425–6  
             carboxylates, 428, **428**, 429, **429**  
             dicarboxylates, 425, 425  
             gibberellate, 425, 425, **425**  
             oxide, 424  
             terebate, 425, 425, **425**  
         F-containing, 428  
         halides, 422  
         mode of action, 431  
         polyoxaalkyl-containing, 430  
         stannates, 428  
         structure in solution, 422  
         therapeutic potential, 431–3  
         tri-*n*-butyltin compounds  
             carboxylates, 431  
             terebate, **426**  
             triphenyl compounds, terebate, **426**  
     porphyrin complexes, 433  
     sulfide, 279  
     therapeutic potential of compounds,  
         421–39  
     triorganotin compounds  
         carboxylates, 426–7, **426**, **426**  
         steroidcarboxylates, 427, **427**  
 Titanium, 85, 125–6, 136, 359  
     anti-cancer drugs, 127–30  
     anti-tumor drugs, 125–42  
     biochemistry, 126–7  
     dioxide, 127, 130  
 Titanocene dichloride, 127–8, 128, 129–31,  
     135–9  
     animal studies, 137  
     chemistry and anti-cancer activity,  
         135–6  
     clinical investigations, 138  
     hydrolytic instability, 138  
     perspectives, 138–9  
     reaction with biomolecules, 136–7, **137**  
 TMH ferrocenase, 181  
 Tocopherols, 323  
 Tolmetin, 182  
*p*-Tolylgermatrane, 287  
 Topoisomerase I, 453  
 Topoisomerase II inhibitors, 202–3  
 Topotecan, 91  
 Torsade de pointes, 60–1  
 Toxicity  
     renal, 138, 267, 270  
     Zn, 251–2  
 TPN  
     and Mn deficiency, 162  
 Transfection, 167  
 Transfer coefficient (TC), 393  
 Transferases, 160  
 Transferrin, 129, 139, 151–3, 181, 263, 270  
     Fe/Mn transport by, 162, 262  
 Transition metals  
     antagonism, 246  
     as contrast agents, 542  
 Transplatin, 495–8, 496  
 Tremors  
     from Li, 14  
*Treponema pallidum*, 298  
 Triamidomonothiol, 339  
 Triazoles, 86, 91, 281  
 Triazolo-2,4-pentanedione, 405  
 Tricarboxylate, 532  
 2,4,6-Trichlorophenoxy, 136

- Trichomonas*, 298  
*Trichophyton*, 431  
     *mentagrophytes*, 91  
 Tricine, 340  
 Tricyclohexyltin carboxylates, 431  
 Triethanolamine, 286–7  
 2-(5'-Triethylgermyl-3'-isoxazoliny)pyridine hydrochloride, 289  
 2-(5'-Triethylgermylmethyl-3'-isoxazoliny)pyridine hydrochloride, 289  
 Triethylphosphine, 514  
     oxide, 514  
 17-(Triethylsilyl)ethynylestradiol, 89  
 Triglycerides, 77  
 Triglydazone, 145  
 Trimethoxysilanes, 96  
 Trimethylamine carboxyborane, 24  
 Trimethylene, 501  
 1-Trimethylgermoxygermatrane, 288  
      $\beta$ -(trimethylgermyl)alanine, 290  
     5-Trimethylgermyluracil, 289  
     (3,5,5-Trimethylhexanoyl)ferrocene, 181, 181  
 Trimethylselenonium, 319  
     1-Trimethylsiloxygermatrane, 288  
      $\beta$ -(trimethylsilyl)alanine, 290  
     4-[3,5-bis(Trimethylsilyl)benzamido]benzoic acid (TAC-101), 93  
     7-Trimethylsilylcamptothecin, 90  
     7-[2-(Trimethylsilyl)ethyl]-20(S)-camptothecin, 90  
     (E)-4-{3-[3,5-bis(Trimethylsilyl)phenyl]-3-oxo-1-propenyl}benzoic acid, 92, 93  
 Triorganogermyl propanoic acid, 431  
 Triostam<sup>®</sup>, 445  
 Tripeptide, 450, 452  
 Triphenylstannate  
     B-based, 432  
     1-Triphenylgermoxygermatrane, 288  
     1-Triphenylgermyl-4-propionyl semicarbazides, 289  
     1-Triphenylgermyl-4-propionyl thiosemicarbazides, 289  
 Triphenylphosphine, 473  
 Triphenylselenonium, 324  
     1-Triphenylsiloxygermatrane, 288  
 Triphenylstannates, 429  
 Triphenyltin sulfanylpropenoates, 432  
 Tripotassium dicitrato bismuthate, 532  
 Trisenox<sup>®</sup>, 298, 308  
 Trisodium bis(thiosulphato)gold, 511–12, 512  
 Trisodium triphenylphosphine-3',3'',3'''-trisulfonate (TPPTS), 340  
 Trithiaazacyclotetradecanes, 391  
 Tropane, 340  
 Tropical disease, 444  
 Tropolone, 536  
 Trypanocides, 388  
*Trypanosoma*, 380  
     *brucei*, 454  
     *congolense*, 388  
     *cruzi*, 388–9, 451, 523  
     *equiperdum*, 388  
     *evansi*, 259, 388  
 Trypanosomes, 433  
     and Rh complexes, 388  
 Trypanosomiasis, 298, 444  
 Trypanothione, 450–3  
     reductase, 450  
     structure, 451–2  
 Trypsin, 202  
 TSAO, 86  
 TSAO-T, 86, 87  
 TSC-pharmacophore, 223  
 Tuberculosis  
     and As, 298  
     and Au, 510  
 Tubulin, 305–6  
 Tumors, 423, 444  
     *see also* Adenocarcinomas; Cancers; Carcinomas  
     ascitic, 134, 136–7, 139, 195  
     autochthonous, 134  
     bone, 260  
     brain, 21, 45  
     breast, 361  
     cervical, 299  
     colon, 134, 361, 410  
     colorectal, 134  
     Ehrlich ascitic, 283, 288, 381  
     gastric, 299  
     inhibitors, 289  
     Landschutz, 381  
     lung, 410, 414

Index

- metastatic, 380
- neuroendocrine, 343
- ovarian, 233, 234–5
- Tyrosine, 13
  - phosphatase, 148, 264
- U937 cell lines, 304
- Ulcerative colitis, 511
  - and Zn deficiency, 241
- Ulcers, 70, **455**
  - and As, 297
  - and Bi, 530
  - and Sb, 444
  - and Zn, 244
- Ullmanite, 441
- Uracil, 281, 283
- Uranium, 334
- Urea, 72, 189–90
- Urease, 72
- Uric acid, 3
- Uridine, 85, 86, 133
- Urine
  - As in, 306
  - Fe in, 181
  - Ga in, 268, 270
  - Rh in, 392
  - Sb in, 448
  - Se in, 314
  - urea in, 3
  - Zn in, 244
- Urticaria, 393
- Uterus
  - myometrial cells, 54
- Vaccines
  - Al in, 80
- Valence-shell electron repulsion theory (VSEPR), 509
- Valproic acid (VPA), 5, 13
- Van der Waals radius, 508
- Vanadates, 143–5, 153–4
- Vanadium
  - action mechanism *in vivo*, 153–5, 153
  - biological and medical aspects, 144
  - chemistry, 143–4
  - complexes
    - with biological activity, 145–8, 146–7
    - speciation in biological fluids, 149–53, 150–1
- compounds
  - activity and toxicity, 148–9
  - speciation, 154, 154
- insulin-mimetic compounds, 143–58
- nitrogenases, 144
- toxicity, 155
- Vanadocene dichloride, 144
- Vanadyl, 143, 145
  - sulfate, 155
- Vectors
  - adenoviral, 167
- Ventricular tachycardia, 61
- Vibrio cholerae*, 404
- Vinblastine, 137
- Vinylgermatrane, 287
- Vitamin B<sub>1</sub>, 163
- Vitamin B<sub>6</sub>, 174
- Vitamin B<sub>12</sub>, 201, 209
- Vitamin C, 243
- Vitamin D, 112, 114–15, 117, 238
  - deficiency, 116, 118
- Vitamin E, 243, 249
- Vitamin K, 162
- Walker's carcinosarcoma, 227, 265–6, 269
- Weight control regulation, 119–20
- WIDR cell lines, 423, **423**, 425, **425–30**
- Wilson disease, 220, 243, 252
- Wnt, 6, 12–13
- World Health Organization (WHO)
  - and Zn use, 240–1, **242**
- Wound healing
  - and Zn, 244
- X-ray crystallography, 343, 468, 513, 531–2, 538
- Xanthate rhodium(I) carbonyl complexes, 380
- Xanthosine monophosphate, 325
- Xenopus*
  - Li effects on, 5
- Yeasts, 406, 521, 537
  - Se-enriched, 315, 318
- Yttrium isotopes, 465, 469

Zebrafish

Li effects on, 5

Zero charge point (zcp), 68–9

Zifrosilone, 89, 90

Zinc, 172, 400, 508

acetate, 245

anti-oxidant role, 246–7

and cancer, 245–51

prostate, 249–51, 250

catalytic, structural and regulatory

functions, 237–8

and common cold, 245

deficiency, 238–40

dietary factors in, 241

and DNA damage, 246

and oxidative stress, 246–7

risk factors for, 241–2

side effects, 239

and DNA repair, 247–9

drug interactions, 252

gluconate, 245, 252

and growth retardation, 239–40

high-dose, 243

intake recommendations, 241–2

intranasal, 245, 251–2

as a metallotherapeutic agent,  
237–57

oxide, 251

safety, 251–2

sulfate, 243, 251

sulfide, 259, 279

and susceptibility to disease,  
240

therapeutic uses, 243–4

toxicity, 251–2

Zirconium oxide, 66

*Index compiled by L.N. Derrick*



